Document:

LICENSE
      AGREEMENT

    (the
      “Agreement”)

    

    

    Effective
      Date: April 22 , 2005 Between

     

    Rosetta
      Genomics Ltd. an Israel company of 10 Plaut Street, Science Park, Rehovot,
      Israel, hereinafter “ROSETTA”

     

    And

     

    Ambion,
      Inc., a Delaware corporation having its principal office at 2130 Woodward St.,
      Austin, Texas 78744, hereinafter “AMBION”. AMBION and ROSETTA may be referred to
      individually as the “Party” or collectively as the “Parties”.

     

    WHEREAS,
      ROSETTA has identified a large number of microRNA sequences using a proprietary
      bioinformatics approach;

     

    WHEREAS,
      AMBION is in the business of designing and developing kits including kits
      directed towards the use of microRNA;

     

    WHEREAS,
      ROSETTA desires to license to AMBION its microRNA sequences, and AMBION desires
      to take such a license;

     

    NOW,
      THEREFORE, in consideration of the premises and mutual promises and covenants
      hereinafter set forth, the parties hereby agree as follows:

     

    1.  DEFINITIONS

     

    The
      following terms, when used in the Agreement, shall have the meanings set forth
      hereinbelow:

     

    A.  ROSETTA
      miRNA SEQUENCES shall mean miRNA sequences that A. (i) have been
      bioinformatically sequenced by ROSETTA or will be bioinformatically sequenced
      by
      ROSETTA in the future during the term of this Agreement, (ii) are the subject
      of
      one or more pending ROSETTA patent applications and (iii) are less than 90%
      homologous to miRNA sequences which are (a) published by third parties in the
      SANGER public registry prior to the Effective Date of this Agreement, or (b)
      published as a VALIDATED miRNA by a third party in a known scientific journal
      prior to the Effective Date of this Agreement, or B. are covered by an issued
      US
      Patent to which ROSETTA has rights. 

     

    Promptly
      upon receipt of any and all sequences from ROSETTA, AMBION shall examine such
      sequences and notify ROSETTA within 30 days (“Notification Period”) whether such
      sequences are 90% or more homologous to miRNA sequence published by a third
      party as set forth in this section (iii) above. Such notification shall include
      all reasonably required references and documentation evidencing the same.
      Following the Notification Period, any miRNA sequences provided by ROSETTA,
      which was not included in such notification shall be regarded as ROSETTA miRNA
      SEQUENCES under this Agreement.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    ROSETTA
      miRNA SEQUENCES includes VALIDATED ROSETTA miRNA SEQUENCES and NON-VALIDATED
      ROSETTA miRNA SEQUENCES.

     

    B.  VALIDATED
      ROSETTA miRNA SEQUENCES shall mean ROSETTA miRNA SEQUENCES which have been
      VALIDATED by ROSETTA prior to the provision of VALIDATED “0”
SEQUENCES.

     

    VALIDATED
      “0” SEQUENCES shall mean 140 (one hundred and forty) VALIDATED ROSETTA miRNA
      SEQUENCES, where up to 50 of such sequences may be published prior to the
      Effective Date.

     

    C.  NON-VALIDATED
      ROSETTA miRNA SEQUENCES shall mean ROSETTA miRNA SEQUENCES which have not been
      VALIDATED by ROSETTA prior to the provision of the VALIDATED “0”
SEQUENCES.

     

    D.  PRODUCT
      shall mean a product that (a) incorporates at least one (1) ROSETTA miRNA
      SEQUENCE, or (b) is designed to detect or otherwise affect ROSETTA miRNA
      SEQUENCE.

     

    E.  LICENSED
      FIELD shall mean use or sale of a PRODUCT solely as a research reagent, as
      in a
      kit format or in the performance of microarray services, specifically excluding
      any use in humans and any clinical diagnostic use.

     

    F.  LICENSED
      PRODUCT shall mean a PRODUCT solely in the LICENSED FIELD.

     

    G.  COMBINATION
      PRODUCT shall mean a LICENSED PRODUCT sold together with one or more other
      products or components of a product, which are not LICENSED
      PRODUCTS.

     

    H.  “MICRORNA”
      (also referred to as “miRNA”) shall mean a short RNA sequence that is encoded in
      the human genome in a hairpin structure, wherein such sequence is predicted
      to
      be expressed and/or is expressed in cells.

     

    I.  NET
      SALES
      shall mean all revenues from sales or other commercial use by Ambion or its
      Affiliates at arms’ length of LICENSED PRODUCTS less the following deductions:
      (i) customary trade, quantity; or cash discounts which are actually granted,
      (ii) amounts repaid or credited by reason of rejection or return, (iii) any
      taxes or other governmental charges levied on the production, sale,
      transportation, or delivery or use of a LICENSED PRODUCT other than income
      taxes
      and property taxes and (iv) outbound transportation costs prepaid or allowed
      and
      actual costs of insurance in transit. Any sales or commercial use not at arms’
length shall be accounted for at arms’ length prices or best approximations
      thereto.

     

    For
      COMBINATION PRODUCTS, NET SALES shall mean revenues from sales by Ambion or
      its
      Affiliates at arms’ length of the COMBINATION PRODUCTS (i) less the deductions
      set forth in the previous paragraph, and (ii) multiplying the resulting sum
      by -
      (a) if all components of the Combination PRODUCT were sold separately during
      the
      same or immediately preceding quarter, the fraction A/A+B where A is the sales
      price of the LICENSED PRODUCT components during such period when sold separately
      from the other components, and B is the sales price of the other components
      during such period when sold separately from the LICENSED PRODUCT
      components;

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
          2

        

        
          

        

      

      
        
        

      

    

    (b) if
      all
      components of the Combination PRODUCT were not sold separately during the same
      or immediately preceding quarter, the fraction [C/(C+D)], where C is the
      manufacturing cost of the ROSETTA miRNA SEQUENCE components and D is the
      manufacturing cost of the other components (manufacturing costs exclude
      packaging, labeling and any other indirect associated costs).

     

    J.  ROYALTY
      BASE FACTOR shall mean a dimensionless number equal to the ratio of the number
      of ROSETTA miRNA SEQUENCES in a given LICENSED PRODUCT to the total number
      of
      sequences included such given LICENSED PRODUCT.

     

    K.  “VALIDATED”
      shall mean a specific miRNA sequence that has been shown via a VALIDATION METHOD
      to be expressed in at least one tissue or cell type.

     

    L.  “VALIDATION
      METHOD.” shall mean (i) sequencing analysis, or (ii) Northern blot analysis, or
      (iii) a method mutually agreed upon by the Parties.

     

    M.  “Affiliate”
      shall mean any entity that directly or indirectly owns, is owned by or is under
      common ownership with a Party hereto, where “owns” or “ownership” means direct
      or indirect possession and/or control of at least fifty percent (50%) of the
      outstanding voting securities of a corporation or a comparable equity interest
      in any other type of entity.

     

    N.  “Intellectual
      Property Rights” shall mean patent rights, copyrights, and trade secret rights,
      and all other rights to inventions including the right to perfect and prosecute
      such rights with appropriate governmental authorities and the rights to enforce
      any and all such rights against third parties and to collect damages and secure
      such other remedies that are available and appropriate.

     

    O.  “Exclusivity
      Factor” shall mean a number equal to the ratio of ROSETTA miRNA SEQUENCES in a
      given LICENSED PRODUCT and/or COMBINATION PRODUCT where such SEQUENCES are
      licensed exclusively by AMBION to the total number of ROSETTA miRNA SEQUENCES
      in
      the same LICENSED PRODUCT and/or COMBINATION PRODUCT.

     

    P.  “EXCLUSIVE
      NET SALES” shill mean the NET SALES of a LICENSED PRODUCT or COMBINATON PRODUCT,
      and if appropriate multiplied by the ROYALTY BASE FACTOR, multiplied by the
      Exclusivity Factor,

     

    2.  LICENSE
      GRANT

     

    A.  ROSETTA
      hereby grants to AMBION a non-exclusive license to make, have made, offer for
      sale, sell, have sold, distribute, have distributed, and use in an AMBION
      service business, and let end-users use the LICENSED PRODUCTS including only
      the
      VALIDATED “0” SEQUENCES. No other use of the ROSETTA miRNA SEQUENCES is licensed
      hereunder. This grant is not subject to sub-license except as set forth below
      in
      Section 3A.

     

    B.  AMBION
      may appoint third parties within AMBION’s normal chain of distribution to sell
      LICENSED PRODUCT (such distributors are collectively referred to as
“Distributors”). The Parties acknowledge and agree that a sale of LICENSED
      PRODUCT by AMBION to an arm’s length Distributor shall constitute an arms length
      transaction and referred to in Section II of this Agreement.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
          3

        

        
          

        

      

      
        
        

      

    

    C.  AMBION
      shall include with all LICENSED PRODUCTS and COMBINATION PRODUCTS a statement
      set forth in Annex
      B
      putting
      forth the restrictions of use of the LICENSED PRODUCTS and COMBINATION PRODUCTS
      by the end-user. AMBION agrees to provide such statement according to the same
      standards that AMBION provides similar licenses on similar products. In the
      event AMBION shall engage with Distributors, AMBION undertakes that such
      Distributors shall include with the sale of such LICENSED PRODUCTS and
      COMBINATION PRODUCTS similar restrictions. In the event that AMBION becomes
      aware of additional requirements that are needed to enforce such a limited label
      license, AMBION agrees to notify ROSETTA of such change; and the Parties shall
      mutually agree on revised language to be included in Annex B.

     

    If
      AMBION
      has knowledge that a third party customer is breaching the limited label license
      set forth in Annex B, AMBION shall promptly notify ROSETTA, and the Parties
      shall mutually agree on how to address such third party customer
      breach.

     

    3.  GRANT
      OF
      OPTIONS

     

    A.  ROSETTA
      hereby grants to AMBION an option to convert the license grant set forth in
      Section 2 hereinabove to an exclusive license. In the event that AMBION converts
      the Section 2 license grant to an exclusive license, the grant shall include
      the
      right for AMBION to sub-license the ROSETTA miRNA SEQUENCES to third parties,
      provided AMBION shall receive ROSETTA’s written approval in advance to any such
      sub-license, and subject to section 5 A (10) hereinafter.

     

    This
      option can be exercised by payment by AMBION to ROSETTA of an EXCLUSIVE UP-
      FRONT LICENSE FEE A, as set forth hereinbelow, within an option period of one
      year from the Effective Date of this Agreement (“Option Period A”). Option
      Period A may be extended for up to two additional years at the request of AMBION
      upon payment of US$[***] per year or part thereof to ROSETTA prior to the
      expiration of Option Period A or an extension thereof.

     

    B.  ROSETTA
      hereby grants to AMBION an option to extend the license grant set forth in
      Section 2 hereinabove to additionally cover NON-VALIDATED ROSETTA miRNA
      SEQUENCES scored A (the “NON-VALIDATED A SEQUENCES”). This option can be
      exercised by payment by AMBION to ROSETTA of an UP-FRONT LICENSE EXTENSION
      FEE
      B, as set forth hereinbelow, within an Option Period B of one year from the
      Effective Date of this Agreement. Rosetta agrees that following AMBION’s payment
      of the UP-FRONT LICENSE EXTENSION FEE B, upon identification of any
      NON-VALIDATED B SEQUENCES within the term of this Agreement to immediately
      forward those newly identified sequences to AMBION as set forth
      above.

     

    C.  ROSETTA
      hereby grants to AMBION an option to extend the license grant set forth in
      Section 2 hereinabove to additionally cover NON-VALIDATED ROSETTA miRNA
      SEQUENCES scored “B” (the “NON-VALIDATED B SEQUENCES”).

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
          4

        

        
          

        

      

      
        
        

      

    

    This
      option can be exercised by payment by AMBION to ROSETTA of an UP- FRONT LICENSE
      EXTENSION FEE C, as set forth hereinbelow, within an Option period C of one
      year
      from the Effective Date of this Agreement. ROSETTA agrees that following
      AMBION’s payment of the UP- FRONT LICENSE EXTENSION FEE C, upon identification
      of any NON-VALIDATED B SEQUENCES within the term of this Agreement to
      immediately forward those newly identified sequences to AMBION as set forth
      above.

     

    D.  ROSETTA
      hereby grants to AMBION an option to extend the license grant set forth in
      Section 2 hereinabove to additionally cover NON-VALIDATED ROSETTA miRNA
      SEQUENCES scored C (the “NON-VALIDATED SEQUENCES”).

     

    This
      option can be exercised by payment by AMBION to ROSETTA of an UP-FRONT LICENSE
      EXTENSION FEE D, as set forth hereinbelow, within an Option Period D of one
      year
      from the Effective Date of this Agreement. ROSETTA agrees that following
      AMBION’s payment of the UP-FRONT LICENSE EXTENSION FEE D, upon identification of
      any NON-VALIDATED C SEQUENCES within the term of this to immediately forward
      those newly identified sequences to AMBION as set forth above.

     

    E.  ROSETTA
      hereby grants to AMBION an option to convert the extended license grant referred
      to in Section 3B hereinabove to an exclusive license, following exercise of
      the
      option set forth in Section 3B.

     

    This
      option can be exercised by payment by AMBION to ROSETTA of an EXCLUSIVE UP-FRONT
      EXTENDED LICENSE FEE E, as set forth hereinbelow, within an option period of
      one
      year from the Effective Date of this Agreement. This option may be extended
      for
      up to two additional years at the request of AMBION, subject to AMBION’s
      exercise of the option according to section 3A above prior to such request,
      and
      upon payment of $[***] to ROSETTA per year or part thereof prior to the
      expiration of the option period or an extension thereof.

     

    F.  ROSETTA
      hereby grants to AMBION an option to convert the extended LICENSE GRANT referred
      to in Section 3C hereinabove to an exclusive license, following exercise of
      the
      option set forth in Section 3C.

     

    This
      option can be exercised by payment by AMBION to ROSETTA of an EXCLUSIVE UP-
      FRONT EXTENDED LICENSE FEE F, as set forth hereinbelow, within an Option Period
      of one year from the Effective Date of this Agreement. This option may be
      extended for up to two additional years at the request of AMBION, subject to
      AMBION’s exercise of the option according to section 3A above prior to such
      request, and upon payment of $[***] to ROSETTA per year or part thereof prior
      to
      the expiration of the option period or an extension thereof.

     

    G.  ROSETTA
      hereby grants to AMBION an option to convert the extended license grant referred
      to in Section 3D hereinabove to an exclusive license, following exercise of
      the
      option set forth in Section 3D.

     

    This
      option can be exercised by payment by AMBION to ROSETTA of an EXCLUSIVE UP-FRONT
      EXTENDED LICENSE FEE G, as set forth hereinbelow, within an Option Period of
      one
      year from the Effective Date of this Agreement. This option may be extended
      for
      up to two additional years at the request of AMBION, subject to AMBION’s
      exercise of the option according to section 3A above prior to such request,
      and
      upon payment of $[***] to ROSETTA per year or part thereof prior to the
      expiration of the option period or an extension thereof.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
          5

        

        
          

        

      

      
        
        

      

    

    H.  The
      parties acknowledge and agree that ROSETTA may desire to exclude one of the
      ROSETTA miRNA SEQUENCES from any license granted in the scope of this Agreement
      (the “Excluded ROSETTA miRNA”). The parties agree, that within three (3) months
      of the Effective Date, to negotiate in good faith the terms of an agreement
      that
      would contemplate the aforementioned objective. The parties contemplate that
      the
      issues that will be discussed during such negotiation shall include (i) that
      the
      sequence of interest must be exclusive to a third party for all fields of use;
      (ii) that ROSETTA must receive significant monetary consideration for the
      removal of such sequence from the field of research, and (iii) the compensation
      to be paid to AMBION (or AMBION’s designee) for the exclusion of such sequence
      from the LICENSED PRODUCTS.

     

    4.  INFORMATION
      TRANSFER AND USE

     

    A.  ROSETTA
      hereby authorizes AMBION and AMBION hereby undertakes to carry out VALIDATION
      of
      the NON-VALIDATED ROSETTA miRNA SEQUENCES. For purposes of this section 4
      VALIDATION shall refer only to Northern Blot analysis that includes screening
      of
      each sequence against between 10 - 15 normal human tissues, as set forth in
      Annex
      D(1)
      of this
      Agreement.

     

    B.  AMBION
      shall promptly make available the results of the aforesaid VALIDATION to ROSETTA
      according to the details specified in Annex
      E
      of this
      Agreement (the “AMBION Results”) for internal use of ROSETTA. ROSETTA may
      incorporate the AMBION Results in patent applications pertaining to 50 ROSETTA
      miRNA SEQUENCES, according to ROSETTA’s preferences and AMBION actual
      performance of VALIDATION pertaining to such ROSETTA miRNA SEQUENCES and
      following a written notice to AMBION of such sequences, but otherwise shall
      not
      disclose the AMBION Results to third parties until the AMBION Results have
      entered the public domain through means that do not violate any duty of
      confidentiality to AMBION or any third party:

     

    C.  ROSETTA
      may disclose the AMBION Results for any purpose (excluding to AMBION’s
      competitors in the LICENSED FIELD) upon payment to AMBION of the consideration
      set forth in Annex
      F
      of this
      Agreement per miRNA sequence that is the subject of the disclosure.

     

    ROSETTA
      shall promptly provide AMBION data in ROSETTA’s possession related to the
      ROSETTA miRNA SEQUENCES generated from microarray experiments pertaining solely
      to the tissues as set forth in Annex B(2) of this Agreement, in order to assist
      in identification of appropriate tissues for Northern Blot
      analysis.

     

    D.  The
      LICENSED PRODUCT and the COMBINATION PRODUCT are listed in Annex
      H
      of this
      Agreement. AMBION shall update Annex H upon the addition or removal of any
      LICENSED PRODUCT and COMBINATION PRODUCT under this Agreement.

     

    5.  PAYMENTS
      TO ROSETTA

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
          6

        

        
          

        

      

      
        
        

      

    

    A.  UP-FRONT
      PAYMENTS

     

    The
      following up-front payments shall be payable by AMBION to ROSETTA on the
      conditions set forth hereinbelow. All up-front payments set forth hereinbelow
      and option period extension payments set forth hereinabove include consideration
      for all services provided by ROSETTA, including research, analysis and transfer
      of information, and are fully chargeable against royalties due to ROSETTA but
      are nonrefundable except for the Up-Front due within five days of the Effective
      Date as set forth in Section 5(A)(1).

     

    Payments
      under subsection 5A1 hereinbelow are creditable against payments payable under
      subsection 5A2 and 3A.

     

    Payments
      under subsection 5A3 hereinbelow are creditable against payments payable under
      subsection 5A6 and 3E.

     

    Payments
      under subsection 5A4 hereinbelow are creditable against payments payable under
      subsection 5A7 and 3F.

     

    Payments
      under subsection 5A5 hereinbelow are creditable against payments payable under
      subsection 5A8 and 3G.

     

    1.  UP-FRONT
      PAYMENT FOR NON-EXCLUSIVE LICENSE TO VALIDATED ROSETTA miRNA SEQUENCES pursuant
      to Section 2 - US$[***] payable within five business days of the Effective
      Date
      of this Agreement (the “First Up-Front”). ROSETTA agrees to provide AMBION
      within 2 business days the VALIDATED “0” SEQUENCES.

     

    ROSETTA
      may publish up to 90 of the VALIDATED “0” SEQUENCES if (a) (i) ROSETTA has
      provided to AMBION at least 50 VALIDATED ROSETTA miRNA SEQUENCES (not included
      in VALIDATED “0” SEQUENCES) within 45 days of ROSETTA’s receipt of the First
      Up-Front, and (ii) ROSETTA publishes any of such 90 VALIDATED “0” SEQUENCES no
      sooner than 75 days from the provision of the 50 VALIDATED ROSETTA miRNA
      SEQUENCES set forth in section (i) above. Or (b) ROSETTA refunds the First
      Up-Front to AMBION within 10 business days of such publications.

     

    In
      addition to the provision of the VALIDATED “0” SEQUENCES, ROSETTA shall forward
      to AMBION (within the same timeframe) via electronic mail (or as otherwise
      agreed between the parties) the sequence listing for the all NON-VALIDATED
      A
      SEQUENCES, all NON-VALIDATED B SEQUENCES, and all NON-VALIDATED C SEQUENCES.
      All
      sequences provided by ROSETTA to AMBION under this Agreement shall be added
      to
      this Agreement as Annex
      A
      thereof.
      For the avoidance of any doubt, unless AMBION exercises the options set forth
      in
      sections 3B, 3C and 3D above, AMBION shall not have any right, including the
      rights defined pertaining to the license grant set forth in section 2 above,
      with regard to all NON-VALIDATED A SEQUENCES, all NON-VALIDATED B SEQUENCES,
      and
      all NON-VALIDATED C SEQUENCES.

     

    2.  EXCLUSIVE
      UP-FRONT LICENSE FEE A is defined as $US[***] and is payable within five days
      of
      exercise of the option set forth in Section 3A but in no event after expiration
      of Option Period A or any extension thereof.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
          7

        

        
          

        

      

      
        
        

      

    

    3.  UP-FRONT
      LICENSE EXTENSION FEE B is defined as $US[***] and is payable within five days
      of exercise of the option set forth in Section 3B but in no event after
      expiration of the applicable Option Period or any extension
      thereof.

     

    4.  UP-FRONT
      LICENSE EXTENSION FEE C is defined as $US[***] and is payable within five days
      of exercise of the option set forth in Section 3C but in event after expiration
      of the applicable Option Period or any extension thereof.

     

    5.  UP-FRONT
      LICENSE EXTENSION FEE D is defined as $US[***] and is payable within five days
      of exercise of the option set forth in Section 3D but in no event after
      expiration of the applicable Option Period or any extension thereof

     

    6.  EXCLUSIVE
      UP-FRONT EXTENDED LICENSE FEE E is defined as $US[***] and is payable within
      five days of exercise of the option set forth in Section 3E but in no event
      after expiration of the applicable Option Period or any extension
      thereof.

     

    7.  EXCLUSIVE
      UP-FRONT EXTENDED LICENSE FEE F is defined as $US[***] and is payable within
      five days of exercise of the option set forth in Section 3F but in no event
      after expiration of the applicable Option Period or any extension
      thereof

     

    8.  EXCLUSIVE
      UP-FRONT EXTENDED LICENSE FEE G is defined as $US[***] and is payable within
      five days of exercise of the option set forth in Section 3G but in no event
      after expiration of the applicable Option Period or any extension
      thereof.

     

    7.  ADDITIONAL
      EXCLUSIVE UP-FRONT EXTENDED LICENSE FEE H is defined as $US[***] and is payable
      on April 1 following the first year in which NET SALES exceed US$[***] following
      exercise of the option set forth in Section 3E.

     

    8.  ADDITIONAL
      EXCLUSIVE UP-FRONT EXTENDED LICENSE FEE I is defined as $US[***] and is payable
      on April 1 following the first year in which NET SALES exceed US$[***] following
      exercise of the option set forth in Section 3F.

     

    9.  ADDITIONAL
      EXCLUSIVE UP-FRONT EXTENDED LICENSE FEE J is defined as $US[***] and is payable
      on April 1 following the first year in which NET SALES exceed US$[***] following
      exercise of the option set forth in Section 3G.

     

    10.  SUBLICENSE
      INCOME. In the event that AMBION shall exercise its right to sub-license the
      ROSETTA miRNA SEQUENCES to third parties with ROSETTA’s Approval according to
      section 3A above, AMBION and Rosetta shall negotiate in good faith the mutual
      distribution of all payments to be associated with such
      sub-license.

     

    B.  ROYALTIES

     

    1.  AMBION
      shall pay to ROSETTA on a calendar quarterly basis, four months following each
      calendar quarter, a royalty of [***]% ([***] PERCENT) of all NET SALES
      multiplied by an appropriate ROYALTY BASE FACTOR, as defined hereinabove, for
      each LICENSED PRODUCT.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
          8

        

        
          

        

      

      
        
        

      

    

    2.  In
      addition to the royalty set forth in Section 5B(1) hereinabove, for LICENSED
      PRODUCTS including at least one ROSETTA miRNA SEQUENCE in respect of which
      an
      option under any of Sections 3A, 3E, 3F and 3G has been exercised by AMBION,
      AMBION shall pay a royalty as set forth below and according to the payment
      terms
      set forth in Section 5B(1):

     

    a.  For
      a
      calendar quarter prior to which cumulative total payments to ROSETTA have not
      exceeded US$[***]% ([***] PERCENT) of EXCLUSIVE NET SALES;

     

    b.  For
      a
      calendar quarter prior to which cumulative total payments to ROSETTA have
      exceeded US$[***], but have not exceeded US$[***]% ([***] PERCENT) of EXCLUSIVE
      NET SALES;

     

    c.  For
      a
      calendar quarter prior to which cumulative total payments to ROSETTA have
      exceeded US$[***], but have not exceeded US$[***]% ([***] PERCENT) of EXCLUSIVE
      NET SALES.

     

    d.  When,
      cumulative total payments to ROSETTA have exceeded US$[***], AMBION shall owe
      no
      further royalties to ROSETTA under this Section 5(B)(2).

     

    3.  Stacking.
      If a third party license is required to use or sell the LICENSED PRODUCTS,
      in
      the sense that without such third party license the LICENSED PRODUCT is bared
      from being used, the Parties agree that the royalty rate set forth in Section
      5(B)(1) shall be reduced by [***] percent for every [***] percent in royalty
      paid to the third party. In no event shall the royalty set forth in Section
      5(B)(1) be less than [***] percent.

     

    In
      the
      event that AMBION wishes to enhance the LICENSED PRODUCT by adding a third
      party
      component or product, which is not required to use or sell the LICENSED
      PRODUCTS, but that AMBION for good reason believes is necessary in order to
      maximize the sales of a LICENSED PRODUCTS and such component or product requires
      a royalty-baring license of such third party, then the parties shall negotiation
      in good faith and agree upon any change of the royalty rate paid to ROSETTA
      set
      forth in section 5(B)(1).

     

    6.  MINIMUM
      ROYALTIES

     

    In
      the
      event that AMBION exercises the exclusivity option set forth in Sections 3A
      as
      set forth in this Agreement, AMBION agrees to pay the minimum royalties as
      set
      forth below, payable on January 31 of the calendar year following the relevant
      year. AMBION payment of the minimum royalties shall be a condition precedent
      to
      continued exclusivity, following exercise of any of the options set forth in
      Sections 3A, 3E, 3F and 3G hereinabove. The payments set forth in Section 5(B)
      made during the relevant year shall be creditable to the minimum royalties
      for
      that year.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
          9

        

        
          

        

      

      
        
        

      

    

     

    
      	
              RELEVANT
                CALENDAR YEAR

            	
              AMOUNT
                (US$)

            
	
              2006

            	
              [***]

            
	
              2007

            	
              [***]

            
	
              2008

            	
              [***]

            
	
              2009

            	
              [***]

            
	
              2010

            	
              [***]

            
	
              2011

            	
              [***]

            
	
              2012

            	
              [***]

            
	
              2013

            	
              [***]

            
	
              2014

            	
              [***]

            
	
              2015

            	
              [***]

            
	
              2016

            	
              [***]

            
	
              2017

            	
              [***]

            
	
              2018

            	
              [***]

            
	
              2019

            	
              [***]

            
	
              2020

            	
              [***]

            

    

     

    7.  THIRD
      PARTY PATENTS AND INDEMNITY

     

    Should
      it
      come to the attention of either ROSETTA or AMBION that any one or more of the
      ROSETTA miRNA SEQUENCES infringes a valid claim of a third party patent (the
      “Third Party Sequence”), AMBION may elect to (i) take a license from such third
      party for the right to use the Third Party Sequence, or (ii) remove the Third
      Party Sequence from the relevant LICENSED PRODUCTS. AMBION shall provide prompt
      written notice to ROSETTA upon the removal of a Third Party Sequence as set
      forth in Section 7(ii) above

     

    ROSETTA
      shall indemnify AMBION for all damages payable to third parties for such
      infringement up to the amount of royalties paid by AMBION to ROSETTA in respect
      of the Third Party Sequence in those LICENSED PRODUCTS.

     

    8.  THIRD
      PARTY COMPETITION

     

    For
      any
      calendar quarter following an earlier calendar quarter in which Invitrogen,
      Applied Biosystems, Perkin Elmer or Strategene or other competitor having a
      similar market share markets a competing research kit containing miRNA sequences
      identical to at least [***]% of the ROSETTA miRNA SEQUENCES contained in a
      LICENSED PRODUCT, and in such earlier quarter AMBION’s sales of such LICENSED
      PRODUCT fell by at least [***]% relative to the average sales of such LICENSED
      PRODUCT for the previous two calendar quarters, AMBION shall have the option
      to
      treat the ROSETTA miRNA SEQUENCES which appear in the competitor’s product, as
      not being subject to the exercise of the option set forth in any of Sections
      3A,
      3E, 3F, and 3G, for the purpose of calculating royalties under Section 5
      hereinabove. Such option shall be exercised by written notification to ROSETTA
      no later than the 15th day of such calendar quarter. In such case, the license
      granted by ROSETTA in respect of such ROSETTA miRNA SEQUENCES shall be
      considered to be non-exclusive.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
          10

        

        
          

        

      

      
        
        

      

    

    9.  ENFORCEMENT
      OF ROSETTA PATENT RIGHTS

     

    ROSETTA
      shall have the right, but not the obligation, to enforce its patents relating
      to
      ROSETTA miRNA SEQUENCES. In such case ROSETTA acts for its own account in terms
      of out-of-pocket costs and recoveries.

     

    Should
      ROSETTA not take action to enforce its patents within 3 months of being
      requested to by AMBION, AMBION may take such action in respect of third party’s
      products competing with AMBION LICENSED PRODUCTS within the LICENSED FIELD
      for
      its own account in terms of costs and recoveries, but shall pay to ROSETTA
      royalties pursuant to Section 5 on the recovery net of out-of-pocket costs
      and
      recoveries.

     

    10.  JOINT
      PATENTS

     

    (a)  Intellectual
      Property Rights belonging to ROSETTA as of the Effective Date of this Agreement
      shall be and remain the property of ROSETTA (the “ROSETTA Background
      Intellectual Property”).

     

    (b)  Intellectual
      Property Rights belonging to AMBION as of the Effective Date of this Agreement
      shall be and remain the property of AMBION (the “AMBION Background Intellectual
      Property”).

     

    (c)  The
      ownership of inventions developed during the term of this Agreement shall be
      determined as follows:

     

    
      	 	
              (i)

            	
              any
                invention created solely by AMBION without the use of ROSETTA Confidential
                Information shall be owned solely by
                AMBION;

            

    

     

    
      	 	
              (ii)

            	
              any
                invention created solely by ROSETTA without the use of AMBION Confidential
                Information shall be owned solely by ROSETTA
                and

            

    

     

    
      	 	
              (iii)

            	
              any
                invention created by (a) at least one AMBION employee and at least
                one
                ROSETTA employee, (b) at least one AMBION employee with the use of
                ROSETTA
                Confidential Information, or (e) at least one ROSETTA employee with
                the
                use of the AMEBION Confidential Information (collectively the “Joint
                Inventions”) shall be jointly owned by the Parties. Neither Party may use
                or license the Joint Inventions to a third party with out the prior
                written consent of the other Party. For sole purposes of determining
                the
                ownership of an invention according to this Section only, ROSETTA’s
                Confidential Information and AMBION’s Confidential Information does not
                include sequences that are made available within a LICENSED PRODUCT
                and/or
                COMBINATION PRODUCT by AMBION to an arm’s length customer within its
                marketing activities in the framework of the sales of LICENSED PRODUCTS
                and/or COMBINATION PRODUCT under this
                Agreement.

            

    

     

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
          11

        

        
          

        

      

      
        
        

      

    

     

    11.  REPORTS

     

    (a)  AMBION
      shall provide quarterly reports of NET SALES and EXCLUSIVE NET SALES to ROSETTA,
      and shall be divided to NET SALES and EXCLUSIVE NET SALES in the US and outside
      the US. Exchange rates related to calculation of the Royalties pertaining to
      NET
      SALES and EXCLUSIVE NET SALES outside the US shall be determined according
      to
      the principles set forth in Annex
      G
      of this
      Agreement.

     

    (b)  AMBION
      shall maintain complete and accurate records of all NET SALES and EXCLUSIVE
      NET
      SALES and any amounts payable to ROSETTA in relation to the same. AMBION shall
      retain such records relating to a given Calendar Quarter for at least three
      (3)
      years after the conclusion of that Calendar Quarter. During such three (3)
      year
      period, ROSETTA shall have the right, at ROSETTA’s expense, to cause an
      independent, nationally-recognized, certified public accountant reasonably
      acceptable to AMBION, who is bound by a suitable confidentiality arrangement
      with AMBION, to inspect AMBION’s and the relevant Affiliates’ records relating
      to NET SALES and EXCLUSIVE NET SALES during normal business hours for the sole
      purpose of verifying any reports and payments delivered under this Agreement.
      Such public accountant will only report to ROSETTA whether or not AMBION is
      in
      compliance with its obligations under this Agreement and shall not disclose
      or
      report to ROSETTA any other information or data to which it has access as part
      of this examination. The parties shall reconcile any underpayment or overpayment
      within thirty (30) days after the accountant delivers the results of the audit.
      ROSETTA may exercise its rights under this Section only once every year and
      only
      with thirty (30) days prior notice to AMBION. Notwithstanding the aforesaid,
      in
      the event that any inspection as aforesaid reveals any underpayment by AMBION
      to
      ROSETTA in respect of any year in an amount exceeding [***]% ([***] percent)
      of
      the amount actually paid by AMBION to ROSETTA in respect of such year, then
      AMBION shall (in addition to paying ROSETTA the shortfall), bear the costs
      of
      such inspection.

     

    (c)  Royalties
      payable hereunder shall be made without any deductions, except for withholding
      tax or any other fiscal deductions from time to time required by the government
      of any country.

     

    Withholding
      tax, if any, levied by a government of any country of the on payments made
      by
      AMBION to ROSETTA hereunder or any part thereof according to the relevant law
      shall be borne by ROSETTA. AMBION will pay such withholding tax to the
      respective taxing authorities and will deduct such amount from the royalty
      due
      to ROSETTA.

     

    AMBION
      shall use its best efforts to enable ROSETTA to claim exception there from
      under
      any double taxation or similar agreement in force and shall produce to ROSETTA
      proper evidence of payments of all withholding taxes,

     

    12.  ROSETTA
      PATENT PROSECUTION

     

    Should
      AMBION wish that ROSETTA file additional applications or expedite applications
      on certain ROSETTA miRNA SEQUENCES, ROSETTA shall do so and AMBION shall pay
      the
      resulting costs. ROSETTA shall deliver to AMBION regarding each patent
      application related to this Agreement the following details: (1) reference
      number, (2) sequence listing: (3) filing date (4) status of application. In
      addition, AMBION’s patent attorney may request ROSETTA’s patent attorney to
      provide additional information regarding the status of ROSETTA’s patent
      applications, according to an agreed upon list of pre defined queries, ROSETTA
      shall decide, according to its sole discretion, which particular information
      it
      will provide to AMBION with regard to such request of information.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
          12

        

        
          

        

      

      
        
        

      

    

    13.  EXISTING
      AND FUTURE ROSETTA PATENT LICENSES

     

    (a)  ROSETTA
      represents that its existing patent licenses do not conflict with the licenses
      and options granted herein.

     

    (b)  Following
      exercise by AMBION of any of the options set forth in Sections 3B, 3C and 3D,
      ROSETTA shall provide prompt notice to AMBION when ROSETTA receives bone fide
      interest from a third party for rights to any research product employing the
      ROSETTA miRNA SEQUENCES set forth in the aforementioned respective option
      Sections, and to deliver to AMBION a copy of any draft agreement with such
      third
      party, edited only to remove any identification of that third party. ROSETTA
      shall not enter into such agreement until the longer of a) 60 days from said
      notice, b) two weeks from delivery to AMBION of the final draft of the agreement
      to be signed. In no event shall ROSETTA begin any such discussions with a third
      party as described herein prior to 6 months from the Effective Date of this
      Agreement, in order to allow AMBION the right to exercise any of the options
      set
      forth in Section 3A, 3E, 3F and 3G. Upon the AMBION’s exercise of any of such
      options, ROSETTA agrees to discontinue all negotiations with any third parties
      regardless of the status of such negotiations.

     

    14.  MOST
      FAVORABLE TERMS

     

    The
      parties acknowledge that ROSETTA may enter into license agreements with third
      parties for the use of miRNA SEQUENCES in research and development. The parties
      also acknowledge that AMBION may be at a significant disadvantage if such third
      parties are given terms that are more favorable than the terms received by
      AMBION in this Agreement, and in the event that such license agreements with
      third parties shall be under identical or similar commercial circumstances,
      both
      parties desire that AMBION shall have the opportunity to consider and accept
      the
      terms being offered to such third party. For purposes of this Section only,
      ROSETTA shall have the option to either (i) provide the terms of interest in
      the
      third party agreement wherein such terms of interest include all royalty amounts
      and or percentages to be paid, all up-front fees to be paid, all option fees,
      all terms related to exclusivity, including, but not limited to, any fees for
      converting from nonexclusive to exclusive, and all other consideration, value
      exchanged and any other material term between the third party and ROSETTA as
      shall be decided by ROSETTA (collectively “Terms of Interest”); or (ii) provide
      a copy of the third party licensee agreement to a mutually agreed upon third
      party (the “Evaluator”) wherein such third party would access whether or not
      such third party license agreement is more or less favorable to AMBION than
      this
      Agreement. In the event that such Evaluator concludes that the third party
      license agreement is more favorable to AMBION than this Agreement, ROSETTA
      agrees to disclose the Terms of Interest to AMBION within fifteen (15) business
      days of the Evaluator’s conclusion. The Parties agree that ROSETTA shall bear
      all reasonable expenses associated with the Evaluator’s review of such third
      party license agreement. AMBION will decide, in its sole discretion, whether
      or
      not the Terms of’ Interest are more favorable to similar terms in this
      Agreement. If AMBION does decide that the Terms of Interest are more favorable,
      this Agreement shall be amended to incorporate all of the Terms of
      Interest.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
          13

        

        
          

        

      

      
        
        

      

    

    15.  SINGLE
      PAYMENT

     

    AMBION
      shall have the option to extend the license set forth in Section 2 on an
      exclusive basis to all ROSETTA miRNA SEQUENCES on a paid-up irrevocable basis
      for a one time advance payment of US$[***] less all payments already paid to
      ROSETTA by AMBION.

     

    16.  TRADEMARK

     

    ROSETTA
      agrees that in exchange for the consideration described in this Agreement that
      it will immediately cease all use of the mark “The MicroRNA
      Company”.

     

    17.  ASSIGNABILITY

     

    This
      agreement shall not be assignable by either Party without the prior written
      consent of the other Party, not to be unreasonably withheld, except that either
      Party may, without such consent of the other Party, assign this Agreement to
      (i)
      an Affiliate, (ii) any purchaser of all or substantial part of its assets in
      the
      line of business to which this Agreement pertain, or (iii) any successor
      corporation resulting from any merger or consolidation of either Party with
      or
      into such corporations.

     

    18.  TERM
      AND
      TERMINATION

     

    (a)  This
      term
      of this Agreement is the lifetime of any patents or patent applications covering
      ROSETTA miRNA SEQUENCES.

     

    AMBION
      may terminate this Agreement at its sole option at any time following the
      expiration of the Option Period A and any extension thereof.

     

    ROSETTA
      may terminate this Agreement for non-payment of any payment due pursuant to
      Section 5, upon 60 days notice to AMBION, specifying the payment due, provided
      that the payment has not been made within the notice period, with interest
      at
      Prime plus 5%.

     

    Upon
      termination of this Agreement, all licenses and options shall terminate
      forthwith and all payments accrued shall be payable within 30 days.

     

    (b)  It
      is
      understood that termination. of this Agreement shall not relieve a Party from
      any liability that, at the time of such termination, has already accrued to
      the
      other Party. The provisions of Article 7, 10, 11, 16, 20, 22 and 23, shall
      survive after the expiration or termination of this Agreement

     

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
          14

        

        
          

        

      

      
        
        

      

    

    

    19.  NOTICES

     

    All
      notices pursuant to this Agreement shall be sent to the parties at their
      addresses set forth hereinbelow by fax, email and registered air mail and shall
      become effective 10 days from the date of transmission:

     

    AMBION:

     

    2130
      Woodward St.

    Austin,
      Texas 78744

    Telephone
      Number: (512) 651 0200

    Facsimile
      Number: (512) 651 0201

    Attention:
      Vice-President of Business Development

    Cc:
      General Counsel

     

    ROSETTA:

     

    10
      Plaut
      St.

    Rehovot,
      Israel

    Telephone
      Number:

    Facsimile
      Number:

    Attention:
      Chief Operation Officer

    Cc:
      Director of business Development

     

    Changes
      in the foregoing notice addresses shall be sent to the parties at their
      addresses set forth hereinabove by fax, email and registered air mail and shall
      become effective 10 days from the date of transmission.

     

    20.  Governing
      Law.
      THIS
      AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE
      WITH, THE LAWS OF THE UNITED STATES AND THE STATE OF NEW YORK WITHOUT REFERENCE
      TO CONFLICT OF LAWS PRINCIPLES AND EXCLUDING THE 1980 U.N. CONVENTION ON
      CONTRACTS FOR THE INTERNATIONAL SALE OF GOODS.

     

               Jurisdiction:
      Venue.
      ALL
      DISPUTES ARISING OUT OF OR RELATED TO THIS AGREEMENT WILL BE SUBJECT TO THE
      EXCLUSIVE JURISDICTION AND VENUE OF THE NEW YORK STATE COURTS (OR, IF THERE
      IS
      EXCLUSIVE FEDERAL JURISDICTION, THE UNITED STATES DISTRICT COURT FOR THE
      SOUTHERN DISTRICT OF NEW YORK), AND THE PARTIES CONSENT TO THE PERSONAL AND
      EXCLUSIVE JURISDICTION OF THESE COURTS.

     

    21.  Force
      Majeure.
      Nonperformance of any Party shall be excused to the extent that performance
      is
      rendered impossible by strike, fire, earthquake, flood, governmental acts or
      orders or restrictions, failure or delay of suppliers, or any other reason
      where
      failure to perform is beyond the reasonable control of the nonperforming
      Party.

     

    22.  IN
      NO
      EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY OR ANY OTHER PERSON FOR
      ANY SPECIAL, CONSEQUENTIAL, EXEMPLARY OR INCIDENTAL DAMAGES (INCLUDING LOST
      OR
      ANTICIPATED REVENUES OR PROFITS RELATING TO THE SAME), ARISING FROM OR RELATING
      TO THIS AGREEMENT OR THE SUBJECT MATTER HEREOF, WHETHER BASED IN CONTRACT,
      TORT
      (INCLUDING NEGLIGENCE OR STRICT LIABILITY) OR OTHERWISE, AND EVEN IF SUCH PARTY
      IS ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF SAME.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
          15

        

        
          

        

      

      
        
        

      

    

    23.  Non-Disclosure.
      For
      purposes of this Agreement, “Confidential Information” means information of a
      confidential or proprietary nature relating to the business, products,
      technology or finances of a Party hereto and designated in writing at the time
      of disclosure as “Confidential” or, in the event of oral disclosure, confirmed
      to be “Confidential” in writing within thirty (30) days after the initial oral
      disclosure, or any information of a third party that has disclosed the
      information under a confidentiality arrangement with a Party hereto. Each Party
      will keep confidential and will not publish or otherwise disclose (except to
      its
      Affiliates, employees, agents or consultants having a need to know) and will
      not
      use for any purpose except for the purposes contemplated by this Agreement,
      any
      Confidential Information of the other Party disclosed during the term of this
      Agreement. Each Party will use at least the same standard of care as it uses
      to
      protect its own proprietary or confidential information to ensure that its
      Affiliates, employees, agents and consultants do not disclose or make
      unauthorized use of the Confidential Information of the other Party, but in
      no
      event less than reasonable care.

     

    Confidential
      Information shall not include any information which the receiving Party can
      prove by competent evidence: (a) is now, or hereafter becomes, through no act
      or
      failure to act on the part of the receiving Party, generally known or available;
      (b) is known by the receiving Party at the time of receiving such information,
      (c) is hereafter furnished to the receiving Party by a third party having the
      legal right to do so and without restriction on disclosure, or (d) is
      independently developed by the receiving Party without the aid, application
      or
      use of the Confidential Information. Confidential Information may be disclosed
      upon order of a court of competent jurisdiction provided that notice is provided
      to the Party that owns such Confidential Information immediately upon the
      receipt of the request for such information. The Party receiving such as request
      shall cooperate fully with the Party that owns such Confidential Information
      in
      all lawful efforts to restrict or resist disclosure of such Confidential
      Information.

     

    24.  The
      relationship of AMBION and ROSETTA established by this Agreement is that of
      independent contractors. Nothing in this Agreement shall be construed to create
      any other relationship between AMBION and ROSETTA. Neither Party shall have
      any
      right, power or authority to assume, create or incur any expense, liability
      or
      obligation, express or implied, on behalf of the other.

     

    25.  Entire
      Agreement.
      The
      terms and provisions contained in the Agreement, including the Exhibits hereto,
      constitute the entire agreement between the Parties regarding the subject matter
      hereof and shall supersede all previous communications, representations,
      agreements or understandings, either oral or written, between the Parties
      concerning such subject matter.

     

    26.  Counterparts.
      This
      Agreement may be executed in counterparts, each of which shall be deemed an
      original, but which together shall constitute one and the same
      instrument.

     

    27.  Severability.
      Should any Section, or portion thereof, of this Agreement be held invalid by
      reason of any law, statute or regulation existing now or in the future in any
      jurisdiction by any court of competent authority or by a legally enforceable
      directive of any governmental body, such Section or portion thereof shall be
      validly reformed so as to reflect the intent of the parties as nearly as
      possible and, if not capable of suitable reformation shall be deemed divisible
      and deleted with respect to such jurisdiction, but the Agreement shall not
      otherwise be affected.

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
          16

        

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF, the Parties hereto have duly executed this License
      Agreement.

     

    AMBION,
      INC.

    

     

    By:
      /s/ Bruce Leander                              

    Title:
      President

             
      Bruce Leander

    

    

    ROSETTA
      GENOMICS LTD.

    

    

    By:
      /s/
      Amir
      Avniel                                 

    Title:
      Chief
      Operation Officer

             
      Amir Avniel

    

    

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
          17

        

        
          

        

      

      
        
        

      

    

    Annex
      A

    

     

     

     

     

     

    
 

    

    

    
      
        
          B-1

        

        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

        
        

      

    

    Annex
      B

    

    Limited
      Terms of License

    

    

    NOTICE
      TO PURCHASER: LIMITED LICENSE

     

    This
      product is sold under licensing arrangement between Ambion, Inc. and Rosetta
      Genomics. The purchase price of this product includes limited, nontransferable
      rights under patents and/or pending patent applications owned by Rosetta
      Genomics to use the product solely within the field of research further
      information on purchasing licenses under the Rosetta patent applications may
      be
      obtained by contacting Rosetta Genomics, Director of Business Development
      BD@Rosettagenomics.com (Phone number to be added).

     

    

    

    

    
      
        
          B-1

        

        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

        
        

      

    

    Annex
      D(1)

    

     

     

     

     

    
 

    

    

    
      
        
          D(1)-1

        

        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

        
        

      

    

    Annex
      D(2)

    

    

     

     

    
 

    

    

    
      
        
          D(2)-1

        

        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

        
        

      

    

    Annex
      E

    

    

    [***]
      should be [***] in a form according to the [***] where the [***]

    
      	 	
              1.

            	
              ROSETTA
                [***]

            

    

    
      	 	
              2.

            	
              [***]description
                of [***] on which the [***]

            

    

    
      	 	
              3.

            	
              [***]
                of the [***] in the [***]accordingly, or in any other [***] upon
                by the
                [***]

            

    

    
      	 	
              4.

            	
              [***]
                of the [***] in the [***]accordingly, or in any other [***] upon
                by the
                [***]

            

    

    
      	 	
              5.

            	
              [***]
                to which the [***] like a [***] as is evident from the [***]accordingly,
                or in any other [***] upon by the
                [***]

            

    

    [***]ROSETTA[***]
      for all [***] on which [***] will be [***]

     

    Example:

    

    
      	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	 	 	 
	
              [***]

            	 	 	 
	
              [***]

            	 	 	 
	
              [***]

            	 	 	 
	
              [***]

            	
              [***]

            	 	 	 
	
              [***]

            	 	 	 
	
              [***]

            	 	 	 
	
              [***]

            	 	 	 

    

    

    

    

    

    
      
        
          E-1

        

        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

        
        

      

    

    Annex
      F

    

    Consideration
      for VALIDATION set forth in Section 4

    

    

    

    In
      consideration for the disclosure of AMBION Results to third parties according
      to
      Section 4 (C), ROSETTA shall pay AMBION for AMBION Results pertaining to
      each ROSETTA miRNA SEQUENCE and tissue, as follows:

     

    a. For
      AMBION Results [***] ROSETTA [***] ROSETTA shall pay AMBION an amount of
      US$[***] per each [***]

     

    b. For
      AMBION Results [***] ROSETTA [***] ROSETTA shall pay AMBION an amount of
      US$[***] per each [***]

     

    c. For
      AMBION Results [***] ROSETTA [***] ROSETTA shall pay AMNION an amount of
      US$[***] per each [***]

     

    

    

    

    
      
        
          F-1

        

        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

        
        

      

    

    Annex
      G

    

    Exchange
      Rate Calculation Principles

    

    

    

    All
      payments due hereunder shall be payable in United States dollars. Conversion
      of
      foreign currency to U.S. dollars shall be made at the conversion rate existing
      in the United States in amounts based on the average rate of exchange as
      calculated on the Web site www.oanda.com.
      If the
www.oanda.com
      Web site
      is not available, AMBION will use the conversion rate as reported in the Wall
      Street Journal on the last working day of the royalty period.

    

    

    

    
      
        
          G-1

        

        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

        
        

      

    

    Annex
      H

    

    LICENSED
      PRODUCTS

    

    

    

    
 

     

     

     

    

      
        
          
            H-1

          

          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities
              Act.Execution
      Copy

    

    

    

    

    

     

    

     

    COLLABORATION
      AND LICENSE AGREEMENT

     

    by
      and
      between

     

    ROSETTA
      GENOMICS, LTD.

     

    and

     

    AMBION
      DIAGNOSTICS, INC.

     

    January
      5, 2006

     

    

    

    

    

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

        
        

      

    

    TABLE
      OF CONTENTS

    

    
      	
              1.

            	
              DEFINITIONS

            	
              1

            
	
              2.

            	
              DEVELOPMENT
                AND COMMERCIALIZATION OF PRODUCTS AND SERVICES

            	
              11

            
	
              2.1

            	
              Development
                Programs.

            	
              11

            
	
              2.2

            	
              Development
                and Commercialization.

            	
              13

            
	
              2.3

            	
              Information
                Updates.

            	
              14

            
	
              2.4

            	
              Joint
                Steering Committee.

            	
              15

            
	
              3.

            	
              CONSIDERATION

            	
              16

            
	
              3.1

            	
              Payment
                of Royalties; Royalty Rates; Accounting and Records.

            	
              16

            
	
              3.2

            	
              Sublicense
                Income

            	
              19

            
	
              4.

            	
              TREATMENT
                OF CONFIDENTIAL INFORMATION; PUBLICITY NON-SOLICITATION.

            	
              19

            
	
              4.1

            	
              Confidentiality.

            	
              19

            
	
              4.2

            	
              Publicity

            	
              20

            
	
              4.3

            	
              Publications
                and Presentations

            	
              20

            
	
              4.4

            	
              Prohibition
                on Solicitation

            	
              21

            
	
              5.

            	
              LICENSE
                GRANTS; RESTRICTIONS ON USE

            	
              21

            
	
              5.1

            	
              Grant
                of Rights to AMBION.

            	
              21

            
	
              5.2

            	
              Grant
                of Rights to ROSETTA.

            	
              22

            
	
              6.

            	
              INTELLECTUAL
                PROPERTY R.IGHTS

            	
              23

            
	
              6.1

            	
              Disclosure
                of Inventions

            	
              23

            
	
              6.2

            	
              Patent
                Coordinators

            	
              24

            
	
              6.3

            	
              Inventorship

            	
              24

            
	
              7.

            	
              FILING,
                PROSECUTION AND MAINTENANCE OF PATENT RIGHTS

            	
              24

            
	
              7.1

            	
              Patent
                Filing, Prosecution and Maintenance

            	
              24

            
	
              7.2

            	
              Legal
                Actions.

            	
              25

            
	
              8.

            	
              TERM
                AND TERMINATION

            	
              27

            
	
              8.1

            	
              Term

            	
              27

            
	
              8.2

            	
              Termination

            	
              27

            
	
              8.3

            	
              Consequences
                of Termination of Agreement

            	
              28

            
	
              8.4

            	
              Surviving
                Provisions

            	
              30

            
	
              9.

            	
              REPRESENTATIONS
                AND WARRANTIES

            	
              30

            
	
              9.1

            	
              Mutual
                Representations and Warranties

            	
              30

            
	
              9.2

            	
              Additional
                Representations of ROSETTA

            	
              30

            
	
              10.

            	
              IDEMNIFICATION

            	
              31

            
	
              10.1

            	
              Idemnification
                of AMBION by ROSETTA

            	
              31

            
	
              10.2

            	
              Indemnification
                of ROSETTA by AMBION

            	
              31

            
	
              10.3

            	
              Conditions
                to Indemnification

            	
              31

            
	
              10.4

            	
              Warrant
                Disclaimer

            	
              32

            
	
              10.5

            	
              No
                Warranty of Success

            	
              32

            
	
              10.6

            	
              Limited
                Liability

            	
              32

            
	
              10.7

            	
              Insurance

            	
              32

            
	
              11.

            	
              DISPUTE
                RESOLUTION

            	
              32

            
	
              11.1

            	
              Dispute
                Resolution

            	
              32

            
	
              12.

            	
              MISCELLANEOUS

            	
              34

            
	
              12.1

            	
              Notices

            	
              34

            
	
              12.2

            	
              Governing
                Law

            	
              34

            
	
              12.3

            	
              Binding
                Effect

            	
              35

            
	
              12.4

            	
              Headings

            	
              35

            
	
              12.5

            	
              Counterparts

            	
              35

            
	
              12.6

            	
              Amendment;
                Waiver

            	
              35

            
	
              12.7

            	
              No
                Third Party Beneficiaries

            	
              35

            
	
              12.8

            	
              Purposes
                and Scope

            	
              35

            
	
              12.9

            	
              Assignment
                and Successors

            	
              35

            
	
              12.10

            	
              Force
                Majeure

            	
              35

            
	
              12.11

            	
              Interpretation

            	
              36

            
	
              12.12

            	
              Integration;
                Severability

            	
              36

            
	
              12.13

            	
              Further
                Assurances

            	
              36

            

    

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

        
        

      

    

    COLLABORATION
      AND LICENSE AGREEMENT

     

    This
      COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of
      January 5, 2006, by and between Rosetta Genomics, Ltd., a corporation organized
      under the country of Israel having an address of 10 Plaut Street, Science Park,
      Rehovot, Israel (“ROSETTA”) and Ambion Diagnostics, Inc., a Delaware corporation
      having an address of 2130 Woodward St., Austin, Texas 78744 (“AMBION”). Each of
      AMBION and ROSETTA is sometimes referred to individually herein as a “Party” and
      collectively as the “Parties.”

     

    WHEREAS,
      ROSETTA has developed confidential and proprietary technology relating to
      microRNA sequences including an algorithm for the prediction of microRNAs,
      techniques for validation of predicted microRNAs on a given material, microRNA
      expression profiling technology, analysis algorithms for the detection of
      biomarkers based on microRNA expression profiling and techniques for
      establishing the relationships between microRNAs and diseases and has identified
      a large number of micro RNA sequences using certain of its proprietary
      technology and/or proprietary materials; and

     

    WHEREAS,
      AMBION is in the business of designing, developing, manufacturing and selling
      diagnostic kits and services, including diagnostic kits and services that use
      microRNA sequences and profiles; and

     

    WHEREAS,
      ROSETTA and AMBION desire to enter into a collaboration for the purpose of
      developing one or more diagnostic tests using ROSETTA’s microRNA sequences or
      microRNA sequences analyzed or identified by ROSETTA and/or certain other
      ROSETTA proprietary technology for use in the diagnosis of prostate cancer;
      and

     

    WHEREAS,
      ROSETTA and AMBION desire to collaborate to develop and commercialize diagnostic
      tests for prostate cancer which incorporate ROSETTA’s microRNA sequences or
      microRNA sequences analyzed or identified by ROSETTA and/or certain other
      proprietary technology of ROSETTA.

     

    NOW,
      THEREFORE, in consideration of the mutual covenants contained herein, and for
      other good and valuable consideration, the Parties hereto, intending to be
      legally bound, hereby agree as follows:

     

    1.  DEFINITIONS

     

    Whenever
      used in this Agreement with an initial capital letter, the terms defined in
      this
      Section 1 shall have the meanings specified.

     

    1.1  “Affiliate”
means,
      with respect to any Party, any Person that, directly or through one or more
      Affiliates, controls, or is controlled by, or is under common control with,
      such
      Party. For purposes of this definition only, “control” means (a) ownership of
      more than fifty percent (50%) of the shares of stock entitled to vote for the
      election of directors, in the case of a corporation, or more than fifty percent
      (50%) of the equity interests in the case of any other type of legal entity,
      (b)
      status as a general partner in any partnership, or (c) any other arrangement
      whereby a Person controls or has the right to control the Board of Directors
      or
      equivalent governing body of a corporation or other entity.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        1

        
          

        

      

      
        
        

      

    

    1.2  “AMBION
      Background Technology”
means
      any Technology used by AMBION, or provided by AMBION for use, in the Development
      Program that is useful in the Field and that is (a) Controlled by AMBION as
      of
      the Effective Date or (b) developed or conceived by employees of, or consultants
      to, AMBION after the Effective Date in the conduct of activities outside the
      Development Program and without the use in any material respect of any ROSETTA
      Technology, ROSETTA Materials or any Program Invention.

     

    1.3  “AMBION
      Materials”
means
      any Proprietary Materials Controlled by AMBION and used by AMBION, or provided
      by AMBION for use, in the Development Program.

     

    1.4  “AMBION
      miRNA Profile”
means
      any Confidential Information Controlled by AMBION and used by AMBION, or
      provided by AMBION for use, in the Development Program during the Term of this
      Agreement with respect to the abundance of a given miRNA Sequence within a
      Tissue Sample of a Prostate Cancer tumor. Any AMBION miRNA Profile is AMBION
      Program Technology or AMBION Background Technology, as the case may
      be.

     

    1.5  “AMBION
      Patent Rights”
means
      any Patent Rights containing one or more claims that cover AMBION
      Technology.

     

    1.6  “AMBION
      Program Technology”
means
      any Program Invention conceived or first reduced to practice by employees of,
      or
      consultants to, AMBION, alone or jointly with Third Parties, without the use
      in
      any material respect of any ROSETTA Technology, ROSETTA Materials or Joint
      Program Technology.

     

    1.7  “AMBION
      Results”
means
      all data and information generated by AMBION in the Development Program or
      otherwise in the Development of Collaboration Products or Collaboration
      Services.

     

    1.8  “AMBION
      Technology”
means,
      collectively, AMBION Background Technology and AMBION Program
      Technology.

     

    1.9  “AMBION
      Tissue Samples”
means
      the tissue or body fluid samples identified by AMBION and used by AMBION, or
      provided by AMBION for use, in the Development Program.

     

    1.10  “Annual
      Net Sales”
means
      the aggregate Net Sales during a particular Calendar Year.

     

    1.11  “Applicable
      Laws”
means
      all Federal, state, local, national and supra-national laws, statutes, rules
      and
      regulations, including any rules, regulations, guidelines or requirements of
      Regulatory Authorities, national securities exchanges or securities listing
      organizations that may be in effect from time to time during the Term and
      applicable to a particular activity hereunder.

     

    1.12  “ASR”
      means
      any analyte specific reagent, as defined in 21 CFR 864.4020, that is exempt
      from
      the 510(k) Premarket Notification Requirements.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        2

        
          

        

      

      
        
        

      

    

    1.13  “Calendar
      Quarter”
means
      the period beginning on the Effective Date and ending on the last day of the
      calendar quarter in which the Effective Date falls, and thereafter each
      successive period of three (3) consecutive calendar months ending on March
      31,
      June 30, September 30 or December 31.

     

    1.14  “Calendar
      Year”
means
      each successive period of twelve (12) months commencing on January 1 and ending
      on December 31.

     

    1.15  “Cancer”
means
      any type of malignant neoplasm which may or may not result in
      metastasis.

     

    1.16  “Collaboration”
means
      the association of ROSETTA and AMBIQN established pursuant to this Agreement
      for
      the purpose of conducting the Development Program in order to Develop and
      Commercialize Collaboration Products and Collaboration Services in the Field
      in
      the Territory.

     

    1.17  “Collaboration
      Product”
means
      any product for Diagnosis of Prostate Cancer that incorporates, or is otherwise
      Derived from, or is designed to detect (a) at least one (1) ROSETTA miRNA
      Sequence or (b) at least one (1) Public miRNA Sequence that is used in the
      Development Program. For purposes of clarity, all Collaboration Products shall
      be listed in Schedule
      3
      attached
      hereto, as updated from time to time by AMBION during the Term.

     

    1.18  “Collaboration
      Service”
means
      any service within the Field that is provided through the use of a Collaboration
      Product or a ROSETTA miRNA profile.

     

    1.19  “Commercialization”
or
      “Commercialize”
means
      any and all activities directed to the commercialization of a Collaboration
      Product or Collaboration Service, including pre-launch and post-launch
      marketing, manufacturing for commercial sale, promoting, detailing,
      distributing, offering to sell or provide and selling or providing a
      Collaboration Product or Collaboration Service, importing or exporting a
      Collaboration Product for sale, providing a Collaboration Service, and
      interacting with Regulatory Authorities regarding the foregoing. When used
      as a
      verb, “Commercializing”
means
      to engage in Commercialization.

     

    1.20  “Confidential
      Information”
means
      (a) with respect to ROSETTA, all tangible embodiments of ROSETTA Technology,
      (b)
      with respect to AMBION, all tangible embodiments of AMBION Technology and (c)
      with respect to each Party, (i) all tangible embodiments of Joint Program
      Technology and (ii) all information, Technology and Proprietary Materials
      disclosed or provided by of on behalf of such Party (the “disclosing Party”)
      pursuant to this Agreement to the other Party (the “receiving Party”) or to any
      of the receiving Party’s employees, consultants, Affiliates or sublicensees;
      provided that none of the foregoing shall be Confidential Information if: (A)
      as
      of the date of disclosure, it is known to the receiving Party or its Affiliates,
      as demonstrated by credible written documentation, other than by virtue of
      a
      prior confidential disclosure to such receiving Party or its Affiliates; (B)
      as
      of the date of disclosure it is in the public domain, or it subsequently enters
      the public domain through no fault of the receiving Party or its Affiliates;
      (C)
      it is obtained by the receiving Party from a Third Party having a lawful right
      to make such disclosure free from any obligation of confidentiality to the
      disclosing Party; or (D) it is independently developed by or for the receiving
      Party without reference to or use of any Confidential Information of the
      disclosing Party as demonstrated by credible written documentation. For purposes
      of clarity, the terms of this Agreement shall constitute Confidential
      Information of each Party.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        3

        
          

        

      

      
        
        

      

    

    1.21  “Control”
or
      “Controlled”
means
      (a) with respect to Technology (other than Proprietary Materials), Patent Rights
      or Confidential Information (including data and results), the possession by
      a
      Party of the right to grant a license or sublicense to such Technology or Patent
      Rights, or provide such Confidential Information as provided herein without
      the
      payment of additional consideration to, and without violating the terms of
      any
      agreement or arrangement with, any Third Party and (b) with respect to
      Proprietary Materials, the possession by a Party of the right to supply such
      Proprietary Materials to the other Party as provided herein without the payment
      of additional consideration to, and without violating the terms of any agreement
      or arrangement with, any Third Party.

     

    1.22  “Derived”
means
      obtained, developed, created, synthesized, designed, derived or otherwise
      generated from or based upon (whether directly or indirectly, or in whole or
      in
      part).

     

    1.23  “Designated
      Senior Officer”
      means,
      with respect, to a Party, the senior officer designated by such Party to have
      final decision-making authority over Disputed Matters which, absent unusual
      circumstances, shall be the President or Chief Executive Officer of such
      Party.

     

    1.24  “Development”
or
      “Develop”
means,
      with respect to each Collaboration Product or Collaboration Service, all
      research and development activities required to obtain Regulatory Approval
      of
      such Collaboration Product or Collaboration Service in the Field and in the
      Territory in accordance with this Agreement to the extent required or, to the
      extent Regulatory Approval is not required, to commence commercial sale thereof
      (including without limitation in
      vitro
      studies,
      animal studies, formulation, process development, clinical studies,
      manufacturing, manufacturing scale-up, development-stage manufacturing, and
      quality assurance quality control development. When used as a verb,
“Developing”
means
      to engage in Development.

     

    1.25  “Development
      Plan”
means
      the written plan describing the Development activities to be carried out by
      each
      Party under the Development Program during the Term commencing with the
      Effective Date. The initial Development Plan is attached hereto as Exhibit A.
      The
      Development Plan consists of two (2) stages, the “Discovery Stage” and the
“Clinical Development Stage.”‘

     

    1.26  “Development
      Program”
means
      the development program to be conducted by the Parties pursuant to Article
      2 of
      this Agreement.

     

    1.27  “Diagnosis”
means
      (a) the determination of (i) the presence of a disease, (ii) the stage,
      progression or severity of a disease, or (iii) the effect on a disease of a
      particular treatment; and/or (b) the selection of patients for a particular
      treatment with respect to a disease.

     

    1.28  “Discovery
      Stage Technology”
means
      any Program Invention arising in the Discovery Stage of the Development
      Program.

     

    1.29  “Discovery
      Stage Patent Rights”
means
      Patent Rights that contain one or more claims covering Discovery Stage
      Technology.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        4

        
          

        

      

      
        
        

      

    

    1.30  “Effective
      Date”
means
      the date first set forth above.

     

    1.31  “FDA”
means
      the United States Food and Drug Administration or any successor agency or
      authority thereto.

     

    1.32  “FDCA”
means
      the United, States Federal Food, Drug, and Cosmetic Act, as
      amended.

     

    1.33  “Field”
means
      the Diagnosis of Prostate Cancer (including without limitation the use of a
      Collaboration Product or the providing of a Collaboration Service for the
      Diagnosis of Prostate Cancer). For purposes of clarity, the Field shall include
      the use, in the Diagnosis of Prostate Cancer, of a Collaboration Product or
      Collaboration Service by a clinical laboratory in a laboratory assay which
      contains an ASR.

     

    1.34  “First
      Commercial Sale”
means,
      with respect to a Collaboration Product or Collaboration Service in any country
      in the Territory, the first sale, transfer or disposition for value or for
      end
      use or consumption or use of such Collaboration Product or services constituting
      such Collaboration Service in such country; provided, that, any sale to an
      Affiliate or Sublicensee will not constitute a First Commercial Sale unless
      the
      Affiliate or Sublicensee is the last entity in the distribution chain of the
      Collaboration Product or Collaboration Service.

     

    1.35  “Force
      Majeure”
means
      any occurrence beyond the reasonable control of a Party that (a) prevents or
      substantially interferes with the performance by such Party of any of its
      obligations hereunder and (b) occurs by reason of any act of God, flood, fire,
      explosion, earthquake, strike, lockout; labor dispute, casualty or accident,
      or
      war, revolution, civil commotion, act of terrorism, blockage or embargo, or
      any
      injunction, law, order, proclamation, regulation, ordinance, demand or
      requirement of any government or of any subdivision, authority or representative
      of any such government. 

     

    1.36  “IDE”
means
      an Investigational Device Exemption (as defined in Title 21 of the United States
      Code of Federal Regulations, as amended from time to time) filed or to be filed
      with the FDA with regard to any Collaboration Product or Collaboration
      Services.

     

    1.37  “Joint
      Program Patent Rights”
means
      Patent Rights that contain one or more claims that cover Joint Program
      Technology.

     

    1.38  “Joint
      Program Technology”
means
      any Program Invention conceived or first reduced to practice jointly by
      employees of, or consultants to, AMBION and employees of, or consultants to,
      ROSETTA.

     

    1.39  “Joint
      Steering Committee”
or
      “JSC”
means
      the Joint Steering Committee of ROSETTA and AMBION representatives established
      pursuant to Section 2.4.

     

    1.40  “Licensed
      Patent Rights”
means
      any ROSETTA Patent Rights or Joint Program Patent Rights that (a) contain one
      or
      more claims that cover any Collaboration Product or Collaboration Service or
      (b)
      are necessary or useful for AMBION to exercise the license granted to it
      pursuant to Section 5.1.1. For purposes of clarity (a) all Licensed Patent
      Rights existing as of the Effective Date are described on Schedule
      2
      attached
      hereto and (b) Schedule
      2
      shall be
      amended by ROSETTA during the Term to include any updates to any filings listed
      therein and to include any new Patent Rights that become Licensed Patent Rights
      for purposes of this Agreement. Whether or not a patent is listed on Schedule
      2
      is not determinative of the ownership or licensed or unlicensed status of such
      patent.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        5

        
          

        

      

      
        
        

      

    

    1.41  “Licensed
      Technology”
means
      any ROSETTA Technology or Joint Program Technology that (a) relates to any
      Collaboration Product or Collaboration Service or (b) is necessary or useful
      for
      AMBION to exercise the license granted to it pursuant to Section
      5.1.1.

     

    1.42  “MicroRNA
      Profiles”
or
      “miRNA
      Profiles”
means
      AMBION miRNA Profiles and ROSETA miRNA Profiles.

     

    1.43  “MicroRNA
      Sequence”
or
      “miRNA
      Sequence”
means
      a
      short RNA sequence that is encoded in the human genome in a hairpin structure,
      wherein such sequence is predicted to be expressed and/or is expressed in cells.
      

     

    1.44  “Net
      Sales”
means
      the gross amount billed or invoiced by AMBION or any of its Affiliates or
      Sublicensees to Third Parties (including, without limitation Distributors)
      throughout the Territory for sales or other dispositions or transfers for value
      of Collaboration Products or the providing of Collaboration Services, less
      (a)
      allowances for normal and customary trade, quantity and cash discounts actually
      allowed and taken, (b) transportation, insurance and postage charges, if prepaid
      by AMBION or any Affiliate or Sublicensee of AMBION and included on any such
      party’s bill or invoice as a separate item, (c) credits, rebates, returns
      (including, without limitation, wholesaler and retailer returns), to the extent
      actually allowed, (d) sales, use and other consumption taxes similarly incurred
      to the extent stated on the invoice as a separate item, and (e) royalties paid
      to Third Parties under a license to an issued or pending patent in the absence
      of which the miRNA Sequence in the Collaboration Product or Collaboration
      Service could not legally be sold or used. In addition, Net Sales are subject
      to
      the following:

     

    If
      AMBION
      or any of its Affiliates or Sublicensees effects a sale, disposition or other
      transfer of a Collaboration Product or provides Collaboration Services to a
      customer in a particular country other than in an arms length transaction solely
      for monetary consideration, the Net Sales of such Collaboration Product or
      Collaboration Service to such customer shall be deemed to be “the fair market
      value” of such Collaboration Product or Collaboration Service. For purposes of
      this subsection (i), “fair market value” shall mean the value that would have
      been derived had such Collaboration Product been sold or Collaboration Service
      been provided as a separate product or service to another customer in the
      country concerned in an arms length transaction solely for monetary
      consideration. For avoidance of doubt, the provision of any Collaboration
      Product to a customer for product evaluation purposes without any consideration
      in the ordinary course of business shall not require the fair market value
      thereof to be included in Net Sales.

     

    1.45  “Non-Validated
      miRNA Sequence”
means
      any miRNA Sequence that is not a Validated miRNA Sequence.

     

    1.46  “Patent
      Rights”
means
      the rights and interests in and to issued patents and pending patent
      applications (which, for purposes of this Agreement, include certificates of
      invention, applications for certificates of invention and priority rights)
      in
      any country or region, including all provisional applications, substitutions,
      continuations, continuations-in-part, divisions, renewals, all letters patent
      granted thereon, and all reissues, reexaminations and extensions thereof, and
      all foreign counterparts of any of the foregoing.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        6

        
          

        

      

      
        
        

      

    

    1.47  “Person”
means
      an individual, sole proprietorship, partnership, limited partnership, limited
      liability partnership, corporation, limited liability company, business trust,
      joint stock company, trust, incorporated association, joint venture or similar
      entity or organization, including a government or political subdivision,
      department or agency of a government.

     

    1.48  “Program
      Invention”
means
      any Technology (including, without limitation, any new and useful process,
      method of manufacture or composition of matter) that is conceived or first
      reduced to practice (actually or constructively) in the conduct of the
      Development Program. Technology that is conceived or reduced to practice by
      either Party and that relates to the development of the platform on which to
      run
      the tests associated with the Development Program shall be Program Technology
      of
      the Party conceiving or reducing such Technology to practice and shall only
      be
      Joint Program Technology if covered by Section 1.38.

     

    1.49  “Proprietary
      Materials”
means
      tangible chemical, biological or physical materials that are furnished by or
      on
      behalf of one Party to the other Party in connection with this Agreement,
      whether or not specifically designated as proprietary by the transferring
      Party.

     

    1.50  “Prostate
      Cancer”
means,
      with respect to a patient. a primary tumor of the prostate of such patient,
      a
      metastatic tumor located outside the prostate of such patient having the same
      genetic makeup as a primary tumor of the prostate in such patient, or a
      condition of such patient’s prostate or other tissue that indicates the
      likelihood of developing a primary tumor of the prostate or such a metastatic
      tumor.

     

    1.51  “Prostate
      Cancer Therapeutic Field”
means
      any Therapy of Prostate Cancer.

     

    1.52  “Public
      miRNA Sequence”
means
      any miRNA Sequence that is used by ROSETTA, or provided by ROSETTA for use,
      in
      the Development Program and that is (a) included in the sequence database of
      the
      Sanger Institute prior to the Effective Date or (b) published as a Validated
      miRNA Sequence by a Third Party in a publicly available scientific journal
      prior
      to the Effective Date; provided that any miRNA Sequence that was published
      or
      entered in the sequence data base of the Sanger Institute by ROSETTA or that
      is
      claimed in a patent application filed by ROSETTA before the publication or
      insertion in the sequence data base of the Sanger Institute by a Third Party
      shall be a ROSETTA miRNA Sequence and not a Public miRNA Sequence.

     

    1.53  “Regulatory
      Approval”
means,
      with respect to any country or region in the Territory, any approval (including,
      without limitation, any pricing approval), product and establishment license,
      registration or authorization of any Regulatory Authority required for the
      manufacture, use, storage, importation, export, transport or sale of a
      Collaboration Product or Collaboration Service for use in the Field in such
      country or region. Regulatory Approval shall include, without limitation, any
      510(k) Pre-Market clearance, FDA Pre-Market Approval and/or IDE.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        7

        
          

        

      

      
        
        

      

    

    1.54  “Regulatory
      Authority”
means
      the FDA or any counterpart of the FDA outside the United States, or other
      national, supra-national, regional, state or local regulatory agency,
      department, bureau, commission, council or other governmental entity with
      authority over the distribution, importation, exportation, manufacture,
      production, use, storage, transport, clinical testing or sale of a Collaboration
      Product or Collaboration Service.

     

    1.55  “Regulatory
      Filings”
means,
      collectively, (a) any 510(k) Pre-Market Notification, PMA, IDE or all other
      similar filings (including, without limitation, any counterparts of any of
      the
      foregoing in any country region in the Territory) as may be required by any
      Regulatory Authority for the Development or Commercialization of a Collaboration
      Product or Collaboration Service within the Field and in the Territory; (b)
      all
      supplements and amendments to any of the foregoing; and (c) all data contained
      in, and correspondence relating to, any of the foregoing.

     

    1.56  “ROSETTA
      Background Technology”
means
      any Technology used by ROSETTA, or provided by ROSETTA for use, in the
      Development Program that is useful in the Field and that is (a) Controlled
      by
      ROSETTA as of the Effective Date or (b) conceived or first reduced to practice
      by employees of, or consultants to, ROSETTA after the Effective Date in the
      conduct of activities outside the Development Program and without the use in
      any
      material respect of any AMBION Technology or any Program Inventions. For
      purposes of clarity, ROSETTA Background Technology includes all ROSETTA miRNA
      Sequences.

     

    1.57  “ROSETTA
      Materials”
means
      any Proprietary Materials Controlled by ROSETTA and used by ROSETTA, or provided
      by ROSETTA for use, in the Development Program.

     

    1.58  “ROSETTA
      miRNA Profile”
means
      any Confidential Information Controlled by ROSETTA and used by ROSETTA, or
      provided by ROSETTA for use, in the Development Program during the Term of
      this
      Agreement with respect to the abundance of a given miRNA Sequence within a
      Tissue Sample of a Prostate Cancer tumor. Any ROSETTA miRNA Profile is ROSETTA
      Program Technology or ROSETTA Background Technology, as the case may
      be.

     

    1.59  “ROSETTA
      miRNA Sequence”
means
      any miRNA Sequence (including without limitation any Validated miRNA Sequence
      and Non-Validated miRNA Sequence) that (a) (i) was bioinformatically predicted
      or validated by ROSETTA prior to the Effective Date or is bioinformatically
      predicted or validated by ROSETTA during the Term of this, Agreement; and (ii)
      is covered by a Valid Claim within a pending patent application; or (b) is
      covered by an issued and unexpired patent within a Valid Claim; or (C) is
      licensed by ROSETTA from a Third Party.

     

    1.60  “ROSETTA
      Patent Rights”
means
      any Patent Rights that contain one or more claims that cover ROSETTA
      Technology.

     

    1.61  “ROSETTA
      Program Technology”
means
      any Program Invention conceived or first reduced to practice by employees of,
      or
      consultants to, ROSETTA, alone or jointly with any Third Party, without the
      use
      in any material respect of any AMBION Technology, AMBION Materials or Joint
      Program Technology.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        8

        
          

        

      

      
        
        

      

    

    1.62  “ROSETTA
      Results”
means
      all data and information generated by ROSETTA in the
      Development Program or otherwise in the Development of Collaboration
Products
      or Collaboration Services.

     

    

    1.63  “ROSETTA
      Technology”
means,
      collectively, ROSETTA Background Technology and ROSETTA Program
      Technology.

     

    1.64  ROSETTA
      Tissue Samples”
means
      the tissue or body fluid samples identified by ROSETTA and used by ROSETTA,
      or
      provided by ROSETTA for use, in the Development Program.

     

    1.65  “Royalty
      Term”
means,
      with respect to each Collaboration Product or Collaboration Service in each
      country in the Territory, the period beginning on the date of First Commercial
      Sale of such Collaboration Product or Collaboration Service in such country
      and
      ending on the expiration of the last to expire Valid Claim in such country
      that
      covers such Collaboration Product or Collaboration Service or its manufacture
      or
      a method of its delivery or of its use.

     

    1.66  “Sublicensee”
means
      any Third Party (other than an Affiliate) to which AMBION grants a sublicense
      in
      accordance with Section 5.1.2. For purposes of clarity, a Sublicensee shall
      not
      include a Distributor (as defined in Section 5.1.3).

     

    1.67  “Technology”
means,
      collectively, all inventions, discoveries, improvements, trade secrets and
      proprietary methods, whether or not patentable, including without limitation:
      (a) methods of production or use of, and structural and functional information
      pertaining to, chemical compounds and (b) data, formulations, processes,
      techniques, know-how and results (including any negative results).

     

    1.68  “Territory”
means
      all countries of the world.

     

    1.69  “Therapy”
means
      the treatment or cure of a disease.

     

    1.70  “Third
      Party”
means
      any party other than AMBION and ROSETTA and their respective
      Affiliates.

     

    1.71  “Tissue
      Samples”
means
      AMBION Tissue Samples and ROSETTA Tissue Samples.

     

    1.72  “Validation
      Method”
means
      (a) sequencing analysis, (b) Northern blot analysis, (c) RT-PCR or (d) any
      other
      method mutually agreed to by the Parties.

     

    1.73  “Valid
      Claim”
means
      any claim of an issued and unexpired patent or a pending patent application
      within the ROSETTA Patent Rights, AMBION Patent Rights or Joint Program Patent
      Rights that (a) has not been finally cancelled, withdrawn, abandoned or rejected
      by any administrative agency or other body of competent jurisdiction, (b) has
      not been permanently revoked, held invalid, or declared unpatentable or
      unenforceable in a decision of a court or other body of competent jurisdiction
      that is unappealable or unappealed within the time allowed for appeal, (c)
      has
      not been rendered unenforceable through disclaimer or otherwise, and (d) is
      not
      lost through an interference proceeding.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        9

        
          

        

      

      
        
        

      

    

    1.74  “Validated
      miRNA Sequence”
means
      any miRNA Sequence that has been shown through practice of a Validation Method
      to be expressed in at least one tissue or cell type.

     

    Additional
      Definitions.
      In
      addition, each of the following definitions shall have the  respective
      meanings set forth in the section of this Agreement indicated
      below:

     

    
      	
              Definition

            	
              Section

            
	 	 
	
              AMBION
                Indemnitees

            	
              10.1

            
	 	 
	
              AMBION
                Infringement

            	
              7.2.2(a)

            
	 	 
	
              Claims

            	
              10.1

            
	 	 
	
              Clinical
                Development Stage

            	
              1.23

            
	 	 
	
              Discovery
                Results Meeting

            	
              2.1.2(a)(ii)

            
	 	 
	
              Discovery
                Stage

            	
              1.23

            
	 	 
	
              Disputed
                Matter

            	
              11.1

            
	 	 
	
              Distributor

            	
              5.1.6

            
	 	 
	
              Filing
                Party

            	
              7.1.4

            
	 	 
	
              Indemnified
                Party

            	
              10.3

            
	 	 
	
              Indemnifying
                Party

            	
              10.3

            
	 	 
	
              Infringement
                Notice

            	
              7.2.1(a)

            
	 	 
	
              IPO
                Share Purchase Right

            	
              5.1.5

            
	 	 
	
              Losses

            	
              10.1

            
	 	 
	
              Patent
                Coordinator

            	
              6.2

            
	 	 
	
              Recipient
                Party

            	
              2.1.2(f)

            
	 	 
	
              Restrictions
                on Use

            	
              5.1.7

            

    

     

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        10

        
          

        

      

      
        
        

      

    

     

    
      	 	 
	
              ROSETTA
                Indemnitees

            	
              10.2

            
	 	 
	
              Sequence
                Notice

            	
              2.1.2(b)

            
	 	 
	
              Sequence
                Notification Period

            	
              2.1.2(b)

            
	 	 
	
              Term

            	
              8.1

            
	 	 
	
              Third
                Party Infringement

            	
              7.2.1.
                (a)

            
	 	 
	
              Third
                Party Payments

            	
              3.1.1(c)

            
	 	 
	
              Transferring
                Party

            	
              2.1.2(f)

            
	 	 
	
              Validating
                Party

            	
              1.38

            

    

     

     

    2.  DEVELOPMENT
      AND COMMERCIALIZATION OF PRODUCTS AND SERVICES

     

    2.1  Development
      Program

     

    2.1.1  Objectives
      of Development Program.
      The
      objectives of the Development Program shall be the identification and
      Development of Collaboration Products and Collaboration Services for
      Commercialization in the Field.

     

    2.1.2  Conduct
      of Development Program.

     

    (a)  Development
      Plan.

     

    (i)  Mutual
      Responsibilities of the Parties.
      The
      initial Development Plan covering the activities to be carried out by the
      Parties under the Development Program commencing on the Effective Date is
      attached hereto as Exhibit
      A.
      Unless
      otherwise agreed, each Party shall conduct its activities in the Discovery
      Stage
      independently of the other Party and shall not be required to share any results
      with the other Party until the Discovery Results Meeting. The Parties may,
      by
      mutual agreement, make adjustments and amendments to the Development Plan as
      reasonably required during the Term of this Agreement, which adjustments and
      amendments shall be attached as an addendum to Exhibit
      A.
      Each
      adjustment and amendment to the Development Plan shall be in writing and shall:
      (a) set forth (i) the activities to be performed with reasonable specificity;
      (ii) the Party that shall be responsible for performing such activities; and
      (iii) a timeline for such activities; and (b} be consistent with the terms
      of
      this Agreement. Each Party agrees to use commercially reasonable efforts to
      perform its respective activities under the Development Plan, with the goal
      of
      identifying at least one (1) diagnostic use within the Field (such as early
      detection, staging of tumor or response to a specific therapy) for Development
      of a Collaboration Product or Collaboration Service. Without limiting the
      foregoing, each party shall (A) commit such scientific resources, including,
      but
      not limited to, consultants, facilities, equipment, and Proprietary Materials,
      as are reasonably necessary to achieve the objectives of the Development Program
      and (B) perform its obligations under the Development Plan in good scientific
      manner and in compliance in all material respects with all Applicable
      Laws.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        11

        
          

        

      

      
        
        

      

    

    (ii)  Discovery
      Results Meeting.
      At the
      conclusion of the Discovery Stage, but in no event later than 12 months after
      the Effective Date, the Parties shall exchange data resulting from their
      activities in the Discovery Stage and shall meet to determine the indications
      to
      be pursued in the Clinical Development Stage, the validation activities to
      be
      conducted in the Clinical Development Stage, and the responsibilities of the
      Parties for such activities (the “Discovery Results Meeting”). The Development
      Plan will be modified to reflect such matters.

     

    (iii)  Tissue
      Sharing.
      ROSETTA
      and AMBION shall disclose to each other, at the Discovery Results Meeting and
      thereafter, the Tissue Samples under each Party’s Control and any data
      Controlled by such party with respect to such Tissue Samples in the event that
      such data would be useful in accomplishing the objectives of the Development
      Program. During the Clinical Development Stage, ROSETTA and AMBION shall provide
      reasonable quantities of Tissue Samples, or portions thereof, to each other
      upon
      reasonable request, which Tissue Samples shall be solely for use in the
      Development Program..

     

    (iv)  Specific
      Responsibilities of ROSETTA.
      Without
      limiting the generality of Section 2.1.2(a)(i), in addition to any
      responsibilities of ROSETTA set forth in the Development Plan, ROSETTA shall
      (A)
      disclose to AMBION any data Controlled by ROSETTA on the date of the Discovery
      Results Meeting and thereafter with respect to the ROSETTA miRNA Sequences
      and
      miRNA Profiles that are related to the Tissue Samples used in the Development
      Program; and (B) use commercially reasonable efforts to perform the expression
      profiling activities, analysis of expression profiling results, identification
      of differentially expressed miRNA Sequences and identification of biomarkers
      and
      relevant patient populations described in the Development Plan with the goal
      of
      developing ROSETTA miRNA Profiles that may be clinically evaluated by AMBION
      during the Clinical Development Stage, using as many Tissue Samples as is
      reasonably necessary to support the utility of such ROSETTA miRNA Profiles
      and/or the related ROSETTA miRNA Sequences; provided, that, notwithstanding
      the
      foregoing, neither Party shall be obligated to analyze more than [***]
      Tissue
      Samples pursuant to the Discovery Phase of the Development Program. At the
      Discovery Results Meeting ROSETTA shall disclose to AMBION the relevant ROSETTA
      miRNA Sequences and/or ROSETTA miRNA Profiles. In addition, during the Clinical
      Development Stage, ROSETTA shall use commercially reasonable efforts to perform
      clinical evaluation of ROSETTA miRNA Sequences and Public miRNA Sequences and
      ROSETTA miRNA Profiles developed by ROSETTA pursuant to the Development Program
      as described in the Development Plan.

     

    (v)  Specific
      Responsibilities of AMBION.
      Without
      limiting the generality of Section 2.1.2(a)(i), in addition to any
      responsibilities of AMBION set forth in the Development Plan, during the
      Clinical Development Stage, AMBION shall (A) supply ROSETTA at AMBION’s expense
      with the type and quantity of AMBION Tissue Samples as are set forth in the
      Development Plan; (B) disclose to ROSETTA any data Controlled by AMBION with
      respect to the miRNA Profiles and ROSETTA miRNA Sequences that are related
      to
      the Tissue Samples used in the Development Program; and (C) use commercially
      reasonable efforts to perform clinical evaluation of ROSETTA miRNA Sequences
      and
      Public miRNA Sequences and ROSETTA miRNA Profiles developed by ROSETTA pursuant
      to the Development Program as described in the Development Plan.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        12

        
          

        

      

      
        
        

      

    

    (b)  Cooperation.
      The
      Parties acknowledge that the implementation of the Development Program will
      require cooperation of the Parties and, in connection therewith agree to
      cooperate in the performance of the Development, Program and, subject to Section
      2.2(a) and the other terms of this Agreement and any confidentiality obligations
      to Third Parties, shall exchange such data, information and materials as are
      reasonably necessary for the other Party to perform its obligations under the
      Development Plan.

     

    (c)  Records.
      Each
      Party shall maintain records of its activities under the Development Program
      in
      sufficient detail, in good scientific manner and otherwise in a manner that
      reflects all work done and results achieved in the performance of the
      Development Program. Without limiting the generality of this Section 2.1.2(c),
      each Party agrees to maintain a policy that rewires its employees and
      consultants to record and maintain all data and information developed during
      the
      Development Program in a manner designed to enable the Parties to use such
      records to establish the earliest date of invention or reduction to
      practice.

     

    (d)  Reports
      and Data.
      Subject
      to Section 2.1.2(a), the Parties shall keep the JSC regularly informed of the
      progress of the Development Program. Without limiting the generality of the
      foregoing, (i) prior to the Discovery Results Meeting, no Confidential
      Information or Technology that is not the subject of a patent or patent
      application will be required to be provided, and (ii) after the Discovery
      Results Meeting, the Parties shall, not less than once each Calendar Quarter
      during the Term (and more frequently if required to keep the JSC sufficiently
      informed), provide to the JSC (i) reports in reasonable detail regarding the
      status of each Party’s activities under the Development Program and (ii) such
      supporting data and information as may be reasonably requested from time to
      time
      by the JSC regarding the Development Program.

     

    (e)  Supply
      of Proprietary Materials.
      For the
      purpose of facilitating the conduct of the Development Program, from time to
      time during the Term after the Discovery Results Meeting, each Party (the
“Transferring Party”) shall supply the other Party (the “Recipient Party”), at
      its sole expense, with Proprietary Materials of the Transferring Party for
      use
      in the Development Program as specified in the Development Plan. In connection
      therewith, each Recipient Party hereby agrees that (a) it shall not use such
      Proprietary Materials for any purpose other than exercising its rights or
      performing its obligations hereunder; (b) it shall use such proprietary
      Materials only in alliance with all Applicable Laws; (c) it shall not transfer
      any such Proprietary Materials to any Third Party without the prior written
      consent of the Transferring Party; except as expressly permitted hereby; (d)
      the
      Recipient Party shall not acquire any right, title or interest in or to such
      Proprietary Materials as a result of such supply by the Transferring Party;
      and
      (e) upon the expiration or termination of the Term, the Recipient Party shall,
      if and as instructed by the Party, either destroy or return any such Proprietary
      Materials that are not the subject of the grant of a continuing license
      hereunder. 

     

    2.2  Development
      and Commercialization.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        13

        
          

        

      

      
        
        

      

    

    2.2.1  Responsibility
      for Development and Commercialization.

     

    (a)  Responsibilities
      of AMBION.
      Subject
      to Section 2.4 and to ROSETTA’S obligations set forth in Section 2.2.1(b),
      AMBION shall be responsible for Commercializing, Collaboration Products and
      Collaboration Services in the Field in the Territory, including without
      limitation (i) to the extent required, the preparation and filing of Regulatory
      Filings and the seeking of Regulatory Approvals for Collaboration Products
      and
      Collaboration Services, as well as all associated official correspondence and
      communications with Regulatory Authorities regarding such matters, (ii)
      reporting to Regulatory Authorities any adverse experience and safety issues
      for
      Collaboration Products and Collaboration Services in compliance with the
      requirements of Applicable Laws, and (iii) the conduct of (A) all activities
      relating to the manufacture and supply of Collaboration Products and the
      providing of Collaboration Services, and (ii) all marketing, promotion, sales,
      distribution, import and export activities (including securing reimbursement,
      sales and marketing and conducting any post-marketing trials or databases and
      post-marketing safety surveillance). All activities related to the Development
      and Commercialization of Collaboration Products and the providing of
      Collaboration Services under this Agreement shall be undertaken at AMBION’S sole
      cost and expense, except as expressly provided in this Agreement.

     

    (b)  Responsibilities
      of ROSETTA.
      Notwithstanding anything to the contrary in Section 2.2.1(a), ROSETTA hereby
      agrees to perform the market development activities in support of Collaboration
      Products and Collaboration Services described on Schedule 4
      attached
      hereto and incorporated herein by reference.

     

    2.2.2  Diligence.
      AMBION
      will exercise commercially reasonable efforts in Developing and Commercializing
      Collaboration Products and Collaboration Service, and in undertaking actions
      required to obtain appropriate Regulatory Approvals necessary to market
      Collaboration Products and Collaboration Services in the Field throughout the
      Territory, such commercially reasonable efforts to be in accordance with the
      efforts and resources an established diagnostic company would use for a product
      owned by it or to which it has rights, which is of similar market potential
      at a
      similar stage in development as the applicable Collaboration Product or
      Collaboration Service, taking into account the proprietary position of the
      Collaboration Product or Collaboration Service, the relative potential efficacy
      of the Collaboration product or Collaboration Service, the regulatory
      requirements involved in its Development and Commercialization, the cost of
      goods and availability of capacity to manufacture and supply the, Collaboration
      Product and provide the Collaboration Service at commercial scale, and other
      relevant factors.

     

    2.3  Information
      Updates.

     

    2.3.1  Updates
      and Reports.
      In
      addition to reports to the JSC regarding the Development Program pursuant to
      Section 2.1(d), AMBION shall keep ROSETTA reasonably informed regarding the
      progress of AMBION’s efforts to Develop and Commercialize Collaboration Products
      and/or Collaboration Services in the Field and in the Territory by providing
      ROSETTA with quarterly reports which shall (a) summarize AMBION’s efforts to
      Develop and Commercialize Collaboration Products and/or Collaboration Services,
      and (b) identify the Regulatory Filings with respect to such Collaboration
      Products and/or Collaboration Services that AMBION or any of its Affiliates
      or
      Sublicensees have filed, sought or obtained in the prior Calendar Quarter or
      reasonably expect to make, seek or attempt to obtain in the following Calendar
      Quarter.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        14

        
          

        

      

      
        
        

      

    

    2.3.2  Adverse
      Event Information.
      In
      addition to the updates described in Section 2.3.1, AMBION shall provide ROSETTA
      with copies of all adverse and product complaint information relating to
      Collaboration Products and/or Collaboration Services as such information is
      compiled or prepared by AMBION in the normal course of business in connection
      with the Development or Commercialization of any Collaboration Product and/or
      Collaboration, Service and, in any event, within time frames consistent with
      reporting obligations under Applicable Laws.

     

    2.3.3  Preparation
      of Regulatory Filings.
      AMBION
      shall consult with ROSETTA in good faith in connection with the preparation
      of
      all Regulatory Filings for Collaboration Products and Collaboration Services.
      AMBION shall consider all comments of ROSETTA in good faith, taking into account
      the best interests of the Collaboration and of the Development and
      Commercialization of the applicable Collaboration Product and/or Collaboration
      Service on a global basis. In addition, subject to any Third Party
      confidentiality obligations, AMBION shall promptly provide ROSETTA with copies
      of any document or other correspondence received from the FDA pertaining to
      any
      Collaboration product and/or Collaboration Service.

     

    2.4  Joint
      Steering Committee.

     

    2.4.1  Establishment.
      ROSETTA
      and AMBION hereby establish the Joint Steering Committee to serve as a forum
      for
      coordination and communication between the Parties with respect to the
      Development Program and in connection with the Development and Commercialization
      by AMBION of Collaboration Products and Collaboration Services. The JSC shall
      serve solely as a forum for such, coordination and communication and shall
      not
      have any authority to make decisions.

     

    2.4.2  Membership.
      Each of
      ROSETTA and AMBION shall designate an equal (not less than two (2)) number
      of
      representatives to the JSC (which may be employees of, or consultants to, such
      Party). Unless otherwise agreed by the Parties, one of AMBION’s representatives
      shall be designated as the Chairman of the JSC. Each Party shall have the right
      at any time to substitute individuals on a permanent or temporary basis, for
      any
      of its previously designated representatives to the JSC by giving written notice
      to the other Party.

     

    2.4.3  Meetings.

     

    (a)  Schedule
      of Meetings; Agenda.
      The JSC
      shall establish a schedule of times or regular meetings, taking into account,
      without limitation, the planning needs of the Collaboration. In addition,
      special meetings may be convened by any member of the JSC upon thirty (30)
      days
      (or, if such meeting is proposed to be conducted by teleconference, upon ten
      (10) days) written notice to the other members. In no event shall the JSC meet
      less frequently than four (4) times in each Calendar Year. Regular and special
      meetings of the JSC may be held in person or by teleconference or
      videoconference; provided that meetings held in person shall alternate between
      the respective offices of the Parties in Austin, Texas and Rehovot, Israel
      or
      such other locations mutually agreeable to the JSC members. The Chairman shall
      have the responsibility for preparing and circulating to each JSC member an
      agenda for each JSC meeting not later than one (1) week prior to such
      meeting,

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        15

        
          

        

      

      
        
        

      

    

    (b)  Minutes.
      The JSC
      shall keep minutes of its meetings that record its discussions and decisions
      in
      reasonable detail. Drafts of the minutes shall be prepared and circulated to
      the
      members of the JSC within a reasonable time after the meeting, not to exceed
      ten
      (10) business days, and the Parties shall alternate responsibility for the
      preparation and circulation of draft minutes. Each member of the JSC shall
      have
      the opportunity to provide comments on the draft minutes. Draft minutes shall
      be
      approved, disapproved and revised as necessary at the next JSC meeting. Upon
      approval, final minutes of each meeting shall be circulated to the members
      of
      the JSC by the Chairman.

     

    (c)  Expenses.
      ROSETTA
      and AMBION shall each bear all expenses of their respective JSC representatives
      related to their participation on the JSC and attendance at JSC
      meetings.

     

    3.  CONSIDERATION

     

    3.1  Payment
      of Royalties; Royalty Rates; Accounting and Records.

     

    3.1.1  Payment
      of Royalties.

     

    (a)  Royalty
      Rates.
      AMBION
      shall pay ROSETTA a royalty based on Annual Net Sales of each Collaboration
      Product and Collaboration Service commencing with the Calendar Year (or partial
      Calendar Year) in which the First Commercial Sale of such Collaboration Product
      or Collaboration Service occurs and ending upon expiration of the Royalty Term
      for such Collaboration Product and Collaboration Service, at the following
      rates:

     

    
      	
              Annual
                Net Sales

            	
              Royalty
                Rate

            
	 	 
	
              Up
                to and including $[***] million

            	
              [***]%

            
	 	 
	
              Above
                $[***] million and up to and including $[***] million

            	
              [***]%

            
	 	 
	
              Above
                $[***] million and up to and including $[***] million

            	
              [***]%

            
	 	 
	
              Above
                $[***] million and up to and including $[***] million

            	
              [***]%

            
	 	 
	
              Above
                $[***] million

            	
              [***]%

            

    

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        16

        
          

        

      

      
        
        

      

    

    For
      purposes of clarity, for example, if Annual Net Sales are equal to $[***]
      million, the royalty payment under this Agreement shall be $[***] million
      ([***]% of $[***]million, plus [***]% of $[***] million, plus [***]% of $[***]
      million). The applicable royalty rates will apply per product and the quantity
      of Annual Net Sales for each such product will be calculated separately for
      each
      Calendar Year.

     

    (b)  Payment
      Dates and Reports.
      Royalty
      payments shall be made by AMBION within thirty (30) days after the end of each
      Calendar Quarter commencing with the Calendar Quarter in which the First
      Commercial Sale of each Collaboration Product and/or Collaboration Service
      occurs. All payments shall be made by wires transfer to the credit of such
      bank
      account as shall be designated in writing from time to time by ROSETTA. ROSETTA
      shall designate a suitable account within thirty (30) days of the Effective
      Date. AMBION shall also provide, at the same time each such payment is made,
      a
      report showing: (i) the Net Sales of each Collaboration Product and
      Collaboration Service by country in the Territory; (ii) the basis for any
      deductions from gross amounts billed or invoiced to determine Net Sales; (iii)
      the applicable royalty rates for such Collaboration Product and Collaboration
      Service; (iv) the exchange rates used in calculating any of the foregoing;
      and
      (v) a calculation of the amount of royalty due to ROSETTA.

     

    3.1.2  Records:
      Audit Rights.
      AMBION
      and its Affiliates and Sublicensees shall keep and maintain for three (3) years
      from the date of each payment of royalties hereunder complete and accurate
      records of their respective gross sales and Net Sales by AMBION and its
      Affiliates and Sublicensees in sufficient detail to allow royalties to be
      determined accurately. ROSETTA shall have the right for a period of three (3)
      years after receiving any such payment to appoint at its expense an independent
      certified public accountant reasonably acceptable to AMBION to inspect or audit
      he relevant records of AMBION and its Affiliates and Sublicensees solely to
      verify that the amount of such payment was correctly determined. AMBION, its
      Affiliates and Sublicensees shall each make its records available for inspection
      or audit by such independent certified public accountant during regular business
      hours at such place or places where such records are customarily kept, upon
      reasonable notice from ROSETTA, solely to verify that royalty payments hereunder
      were correctly announced for or determined. Such inspection or audit right
      shall
      not be exercised by ROSETTA more than once in any Calendar Year or more than
      once with respect to sales of a particular Collaboration product or
      Collaboration Service in a particular period, whichever is less frequent. All
      records made available for inspection or audit shall be deemed to be
      Confidential Information of AMBION and, at AMBION’s request, the accountant
      shall enter into a confidentiality agreement with both Parties substantially
      similar to Section 4.1 limiting the disclosure and use of such information.
      The
      result of each inspection or audit, if any, shall be binding on both Parties.
      In
      the event there was an underpayment by AMBION hereunder, AMBION shall promptly
      (but in any event no later than thirty (30) days after AMBION’s receipt of the
      independent accountant’s report so concluding) make payment to ROSETTA of any
      shortfall. In the event that there was an overpayment by AMBION’s hereunder,
      ROSETTA shall promptly (but in any event no later than thirty (30) days after
      ROSETTA’s receipt of the independent accountant’s report so concluding) refund
      to AMBION the excess amount. ROSETTA shall bear the full cost of such audit
      unless such audit discloses an underreporting by AMBION of more than [***]
      percent ([***]%) of the aggregate amount of royalties payable in any Calendar
      Year, in which case AMBION shall reimburse ROSETTA for all costs incurred by
      ROSETTA in connection with such inspection or audit.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        17

        
          

        

      

      
        
        

      

    

    3.1.3  Overdue
      Royalties.
      All
      royalty payments not made within the time period set forth in Section 3.1.1
      shall bear interest at a rate of [***] percent ([***]%) per month from the
      due
      date until paid in full or, if less, the maximum interest rate permitted by
      Applicable Laws. Any such overdue royalty shall, when made, be accompanied
      by,
      and credited first to, all interest so accrued.

     

    Withholding
      Taxes.
      Withholding tax, if any, levied by a government of any country of the on
      payments made by AMBION to ROSETTA hereunder or any part thereof according
      to
      the relevant law shall be borne by ROSETTA. AMBION will pay such withholding
      tax, to the respective taxing authorities and will deduct such amount front
      the
      royalty due to ROSETTA. AMBION shall use its best efforts to enable ROSETTA
      to
      claim exception there from under any double taxation or similar agreement in
      force and shall produce to ROSETTA proper evidence of payments of all
      withholding taxes. Notwithstanding the foregoing, ROSETTA represents and
      warrants that ROSETTA’s tax documentation, including, but not limited to its
      W-9, on file with AMBION as of the Effective Date is accurate.

     

    3.1.4  All
      payments made by AMBION hereunder shall be free and clear of any taxes, duties,
      levies, fees or charges except for applicable withholding taxes, if any. AMBION
      shall make any applicable withholding payments due from ROSETTA on its behalf
      and shall promptly thereafter provide ROSETTA with written documentation of
      any
      such payment sufficient to enable ROSETTA to satisfy the requirements of any
      taxing authority with regard to an application for a foreign tax credit for
      such
      payment.

     

    3.1.5  Foreign
      Currency Exchange.
      All
      royalty payments shall be payable in full in United States Dollars, regardless
      of the countries in which sales are made. For the purpose of computing Net
      Sales
      for Collaboration Products or Collaboration Services in any currency other
      than
      United States Dollars, the quarterly royalty payment will be calculated as
      follows:

     

    (A/B)
      x C
      = United States Dollars royalty payment on Net Sales sold in any currency other
      than United States Dollars during a Calendar Quarter, where

     

    A=
      foreign “Net Sales” (as defined above) in such Calendar Quarter expressed in
      such foreign currency;

     

    B=
      foreign exchange conversion rate, expressed in local currency of the foreign
      country per United States Dollar (using, as the applicable foreign exchange
      rate, the daily rate of exchange set forth on the web site www.oanda.com
      or, to
      the extent the web site is not available, as published in the Wall Street
      Journal); and

     

    C=
      the
      royalty rate(s) applicable to such Net Sales under this Agreement.

     

    3.1.6  Acknowledgement.
      AMBION
      recognizes and acknowledges that each of the following, separately and together,
      has substantial economic benefit to AMBION: (i) ROSETTA’s expertise concerning
      the discovery and understanding of miRNAs; (ii) the performance by ROSETTA
      of
      the Development Program; (iii) the disclosure to AMBION of results obtained
      in
      the Development Program by ROSETTA; (iv) the licenses granted to AMBION
      hereunder with respect to ROSETTA Technology and Joint Technology are not within
      the claims of any Patent Rights Controlled by ROSETTA; (v) the licenses granted
      to AMBION under Patent Rights Controlled by ROSETTA; and (vi) the exclusivity
      afforded to AMBION by each of the foregoing the Parties agree that the royalty
      rates set forth in Section 3.1.1 reflect a fair and reasonable blended
      allocation of the values provided by ROSETTA to AMBION, regardless of whether,
      any particular Collaboration Product or Collaboration Service contains or uses
      one or more ROSETTA miRNAs.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        18

        
          

        

      

      
        
        

      

    

    3.2  Sublicense
      Income.
      In the
      event that AMBION grants a sublicense to a Third Party that is not an Affiliate
      in accordance with Section 5.1.2, the Parties shall negotiate in good faith
      the
      consideration to be paid to ROSETTA as a result of each such
      sublicense.

     

    4.  TREATMENT
      OF CONFIDENTIAL INFORMATION;

     

    PUBLICITY
      NON-SOLICITATION.

     

    4.1  Confidentiality.

     

    4.1.1  Confidentiality
      Obligations.
      ROSETTA
      and AMBION each recognizes that the other Party’s Confidential Information and
      Proprietary Materials constitute highly valuable assets of such other Party.
      ROSETTA and AMBION each agrees that, subject to Section 4.1.2, during the Term
      and for an additional five (5) years thereafter, it will not disclose, and
      will
      cause its Affiliates and sublicensees not to disclose, any Confidential
      Information or Proprietary Materials of the other Party. In addition, each
      Party
      agrees that it will not use, and will cause its Affiliates not to use, any
      Confidential Information or Proprietary Materials of the other Party except
      as
      expressly permitted hereunder. Without limiting the generality of the foregoing,
      each Party shall take such action, and shall cause its Affiliates and
      sublicensees to take such action, to preserve the confidentiality of the other
      Party’s Confidential Information and Proprietary Materials as such Party would
      customarily take to preserve the confidentiality of its own Confidential
      Information and Proprietary Materials.

     

    4.1.2  Limited
      Disclosure.
      ROSETTA
      and AMBION each agrees that disclosure of its Confidential Information or any
      transfer of its Proprietary Materials maybe made by the other Party to any
      employee, consultant or Affiliate of such other Party to enable such other
      Party
      to exercise its rights or to carry out its responsibilities under this
      Agreement; provided that any such disclosure or transfer shall only be made
      to
      Persons who are bound by the written obligations as described in Section 4.13.
      In addition, ROSETTA and AMBION each agrees that the other Party may disclose
      its Confidential Information (a) on a need-to-know basis to such other Party’s
      legal and financial advisors, (b) as reasonably necessary in connection with
      an
      actual or potential (i) permitted sublicense of such ether Party’s rights
      hereunder, (ii) debt or equity financing of such other Patty or (iii) permitted
      assignment of this Agreement pursuant to Section 12.9 involving such other
      Party
      and (c) if the Person receiving such Confidential Information or Proprietary
      Materials of the other Party agrees in writing to maintain the confidentiality
      of such Confidential Information or Proprietary Materials of the other Party
      with terms at least as restrictive as those contained in Section 4.1.1. In
      addition, each Party agrees that the other Party may disclose such Party’s
      Confidential Information or Proprietary Materials (A) as reasonably necessary
      to
      file, prosecute or maintain Patent Rights, or to file, prosecute or defend
      litigation related to Patent Rights, in accordance with this Agreement; or
      (B)
      as required by Applicable Laws; provided that; in the case of any disclosure
      under this clause (B) the disclosing Party shall (1) if practicable, provide
      the
      other Party with reasonable advance notice of and an opportunity to comment
      on
      any such required disclosure, (2) if requested by such other Party, seek, or
      cooperate in all reasonable respects with such other Party’s efforts to obtain,
      confidential treatment or a protective order with respect to any such disclosure
      to the extent available at such other Party’s expense, and (3) use good faith
      efforts to incorporate the comments of such other Party in any such disclosure
      or request for confidential treatment or protective order.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        19

        
          

        

      

      
        
        

      

    

    4.1.3  Employees
      and Consultants.
      ROSETTA
      and AMBION each hereby represents that all of its employees and consultants,
      and
      all of the employees and consultants of its Affiliates, who participate in
      the
      activities of the Collaboration or (except for routine maintenance or cleaning
      staff) have access to Confidential Information or Proprietary Materials of
      the
      other Party are or will, prior to their participation or access, be bound by
      written obligations to maintain such Confidential Information or Proprietary
      Materials in confidence and not to use such information except as expressly
      permitted hereunder. Each Party agrees to use, and to cause its Affiliates
      to
      use, reasonable efforts to enforce such obligations.

     

    4.2  Publicity.
      The
      Parties acknowledge that the terms of this Agreement constitute Confidential
      Information of each Party and may not be disclosed except as permitted by
      Section 4.1.2. Notwithstanding anything to the contrary in Section 4.1, (i)
      either Party may disclose the existence of this Agreement and the nature and
      scope of the Collaboration, and (ii) the Parties, upon the execution of this
      Agreement, shall mutually agree to a press release with respect to this
      Agreement and, once such press release is approved for disclosure by both
      parties, either Party may make subsequent public’ disclosure of the contents of
      such press release without further approval of the other Party. Thereafter,
      neither Party shall publish, present or otherwise disclose publicly any material
      related to the Development Program or to the Development or the
      Commercialization of a Collaboration Product or Collaboration Service without
      the prior written consent of the other Party.

     

    4.3  Publications
      and Presentations.
      The
      Parties acknowledge that scientific publications must be strictly monitored
      to
      prevent any adverse effect from premature publication or dissemination of
      results of the activities hereunder. Except as required by Applicable Laws,
      each
      Party agrees that it shall not publish or present, or permit to be published
      or
      presented, the results of the Development Program or the Development or
      Commercialization of a Collaboration Product or Collaboration Service, including
      but not limited to, studies or clinical trials carried out by such Party as
      part
      of the Collaboration under this Agreement, without the prior review by and
      the
      approval of the other Party. Each Party shall provide to the other Party the
      opportunity to review any of the submitting Party’s proposed abstracts,
      manuscripts or presentations (including information to be presented verbally)
      which relate to the Development Program or the Development or the
      Commercialization of a Collaboration Product or Collaboration Service at least
      thirty (30) days prior to its intended presentation or submission for
      publication, and such submitting Party agrees, upon written request from the
      other Party within such thirty (30) day period, not to submit such abstract
      or
      manuscript for publication or to make such presentation until the other Party
      is
      given up to sixty (60) days from the date of such written request to seek
      appropriate patent protection for any material in such publication or
      presentation which the other Party reasonably believes is patentable. Once
      such
      abstracts, manuscripts or presentations have been reviewed by the other Party,
      the same abstracts, manuscripts or presentations do not have to be provided
      again, to the either Party for review for a later submission for publication.
      Each Party also shall have the right to require that its Confidential
      Information that is disclosed in any such proposed publication or presentation
      be deleted prior to such publication or presentation. In any permitted
      publication or presentation by a Party, the other Party’s contribution shall be
      duly recognized and co-authorship shall be determined in accordance with
      customary industry standards.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        20

        
          

        

      

      
        
        

      

    

    4.4  Prohibition
      on Solicitation.
      Without
      the written consent of the other Party, neither Party nor its Affiliates shall,
      for a period of five (5) years from the Effective Date, solicit (directly or
      indirectly) any employee of the other Party or its Affiliates who participated
      in the Development Program at anytime. This provision shall not restrict either
      Party or its Affiliates from advertising employment opportunities in any manner
      that does not directly target the other Party or its Affiliates.

     

    5.  LICENSE
      GRANTS; RESTRICTIONS ON USE

     

    5.1  Grant
      of Rights to AMBION.

     

    5.1.1  License
      Grant. Subject to the other terms, of this Agreement (including without
      limitation Section 5.1.4), ROSETTA hereby grants to AMBION during the Royalty
      Term an exclusive (as to all Third Parties and as to ROSETTA), royalty-bearing
      license, including the right to grant sublicenses as described in Section 5.1.2,
      under the Licensed Technology and the Licensed Patent Rights (a) to Develop
      Collaboration Products and Collaboration Services under the Development Program
      in accordance with the Development Plan for use in the Field; and (b) to
      Commercialize and have Commercialized Collaboration Products and Collaboration
      Services for use in the Field and in the Territory. For purposes of clarity,
      it
      is acknowledged that the use by ROSETTA of the Licensed Technology and Licensed
      Patent Rights, including without limitation, ROSETTA miRNA Sequences, and all
      Collaboration Products in (a) its own research and product development
      activities, (b) academic collaborations, and (c) collaborations with Third
      Party
      commercial entities to discover, develop and commercialize therapeutic or
      diagnostic products and/or services outside the Field shall not be deemed to
      be
      Development or Commercialization of Collaboration Products or Collaboration
      Services.

     

    5.1.2  Right
      to Sublicense.
      AMBION
      shall have the right to grant to sublicenses under the license granted to it
      under Section 5.1.1 to any Affiliate or Third Party; provided, that (a) AMBION
      shall have obtained the prior written approval of ROSETTA to each such
      sublicense to a Third Party, (b) it shall be a condition of any such sublicense
      that such Sublicensee agrees in writing with ROSETTA to be bound by (i) all
      terms of this Agreement applicable to the Commercialization of Collaboration
      Products and Collaboration Services in the Field in the Territory (including,
      without limitation, Article 4) and (ii) the Restrictions on Use set forth on
      Schedule 5 attached hereto as described in Section 5.1.4; and (c) AMBION shall
      not be relieved of any of its obligations pursuant to this Agreement as a result
      of such sublicense.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        21

        
          

        

      

      
        
        

      

    

    5.1.3  Appointment
      of Distributors.
      AMBION
      shall have the right to appoint one or more Third Parties within AMBION’s normal
      chain of distribution to act as distributors of Collaboration Products (each,
      a
“Distributor”), provided, that, any sale or transfer for value of a
      Collaboration Product to such Distributor shall be included in the definition
      of
      Net Sales at the transfer price to the Distributor in the event of a transfer
      for value.

     

    

     

    5.1.4  Restrictions;
      Labeling

     

    (a)  Restrictions
      on Use.
      AMBION
      shall include with all Collaboration Products sold by it or any; Affiliate
      to
      any Third Party, and shall require any Sublicensee or Distributor to include
      with respect to all Collaboration Products sold by such Sublicensee or
      Distributor the restrictions on use substantially in the form set forth in
      Schedule 5, attached hereto (the “Restrictions on Use”). AMBION agrees to
      include such Restrictions on Use with Collaboration Products according to the
      same, standards that AMBION provides similar license restrictions on products
      sold by AMBION. In the event that AMBION becomes aware of additional
      requirements that are needed to enforce the Restrictions on Use, AMBION agrees
      to notify ROSETTA of such requirements, and the Parties shall mutually agree
      on
      revised language to be included in Schedule
      5.

     

    (b)  Notice
      of Breach.
      If at
      any time during the Term, AMBION has knowledge that a Third Party purchaser
      of a
      Collaboration Product is breaching the Restrictions on Use, AMBION shall
      promptly notify ROSETTA, and the Parties shall mutually agree on how to address
      such Third Marty breach.

     

    (c)  Labelling.
      In
      addition to the Restrictions on Use, AMBION shall include on the packaging
      of
      Collaboration Products any additional language and/or graphics reasonably
      requested by ROSETTA in the form provided by ROSETTA (including without
      limitation language that discloses that the applicable Collaboration Product
      incorporates ROSETTA Technology), the exact wording and/or design of which
      to be
      determined by mutual agreement of the Parties at the time of Commercialization
      of each such Collaboration Product.

     

    5.1.5  Use
      of
      Results.
      AMBION
      shall have the right to use or incorporate the ROSETTA Results in patent
      applications (or the prosecution thereof) pertaining to AMBION miRNA Sequences
      but only to the extent necessary or useful to support claims solely owned by
      AMBION and in which ROSETTA has no ownership interest.

     

    5.2  Grant
      of Rights to ROSETTA.

     

    5.2.1  License
      Grant.
      Subject
      to the ether terms of this Agreement. AMBION hereby grants to ROSETTA and its
      Affiliates during the Term, a personal, non transferable royalty-free license,
      without the right to grant sublicenses, under AMBION Technology and AMBION
      Patent Rights and AMBION’s interest in Joint Program Technology and Joint
      Program Patent Rights for the sole purpose of fulfilling its obligations under
      the Development Program in accordance with the Development Plan.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        22

        
          

        

      

      
        
        

      

    

    5.2.2  Use
      of
      Results.
      ROSETTA
      shall have the right to use or incorporate the AMBION Results in patent
      applications (or the prosecution thereof) pertaining to ROSETTA miRNA Sequences
      but only to the extent necessary or useful to support claims solely owned by
      ROSETTA and in which AMBION has no ownership interest

     

    5.2.3  No
      Other Rights.
      Except
      as expressly set forth herein, AMBION shall have no rights to use or otherwise
      exploit ROSETTA Technology, ROSETTA Patent Rights or ROSETTA Materials
      (including without limitation ROSETTA miRNA Sequences or ROSETTA miRNA
      Profiles).

     

    6.  INTELLECTUAL
      PROPERTY R.IGHTS

     

    6.1  Disclosure
      of Inventions.
      Each of
      ROSETTA and AMBION shall promptly provide the other Party through the Patent
      Coordinators with written notice concerting all Program Inventions that are
      conceived or reduced to practice in the conduct of the Development Program
      by
      employees or consultants of either of them or their Affiliates, alone or jointly
      with employees or consultants of the other Party or its Affiliates. The Parties
      shall, through the Patent Coordinators, amend Schedule 2
      from
      time to time during the Term to list any Program, Inventions that are Licensed
      Patent Rights.

     

    6.1.1  ROSETTA
      Intellectual Property Rights.
      ROSETTA
      shall have sole and exclusive ownership of all right, title and interest on
      a
      worldwide basis in and to any and all ROSETTA Technology and ROSETTA Patent
      Rights, subject to the rights of, and the licenses granted to, AMBION as set
      forth herein.

     

    6.1.2  AMBION
      Intellectual Property Rights.
      AMBION
      shall have sole and exclusive ownership of all right, title and interest on
      a
      worldwide basis in and to any and all AMBION Technology and AMBION Patent
      Rights, subject to the rights of, and the licenses granted to, ROSETTA as set
      forth herein.

     

    6.1.3  Joint
      Program Technology Rights.
      AMBION
      and ROSETTA shall jointly own all Joint Program Technology and Joint Program
      Patent Rights, subject to the rights of, and the licenses granted to, each
      Party
      hereunder. Notwithstanding anything to the contrary contained herein or under
      Applicable Law, the Parties hereby agree that either Party may use or license
      or
      sublicense to Affiliates or Third Parties all or any portion of its interest
      in
      Joint Program Technology or Joint Program Patent Rights for any purposes outside
      the Field and the Prostate Cancer Therapeutic Field without the prior written
      consent of the other Party, without restriction and without the obligation
      to
      provide compensation to the other Party. Within the Field, only AMBION shall
      have the right to use, license or sublicense any interest in the Joint Program
      Technology, subject to Section 5.1.2. Within the Prostate Cancer Therapeutic
      Field, either Party may use or license or sublicense to Affiliates or Third
      Parties all or any portion of its interest in Joint Program Technology or Joint
      Program Patent Rights; provided that (i) [***] percent ([***]%) of license
      fees
      and royalties from any license or sublicense of such Joint Technology by itself
      (and without any license to any other Technology or Patent Rights of the
      licensing Party) shall be paid to the licensing Party and [***] percent ([***]%)
      shall be paid to the other Party; and (ii) [***] percent ([***]%) of license
      fees and royalties from any licenses or sublicenses of Joint Program Technology
      or Joint Program Patent Rights in combination with other Technology or Patent
      Rights of the licensing Party, shall be allocated to the licensing Party and
      [***] percent ([***]%) shall be allocated to the other Party.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        23

        
          

        

      

      
        
        

      

    

    6.2  Patent
      Coordinators.
      ROSETTA
      and AMBION shall each appoint a patent coordinator (each, a “Patent
      Coordinator”), who shall serve as such Party’s primary liaison with the other
      Party on matters relating to patent filing, prosecution, maintenance and
      enforcement. Each Party may replace its Patent Coordinator at any time by notice
      in writing to the other Party.

     

    6.3  Inventorship.
      In case
      of a dispute between ROSETTA and AMBION over inventorship, such dispute shall
      be
      resolved by application of United States patent law by patent counsel selected
      by the JSC who (and whose firm) is not at the time of the dispute, and was
      not
      at an time during the five (5) years prior to such dispute, performing services
      for either of the Parties. Expenses of such patent counsel shall be shared
      equally by the Parties.

     

    7.  FILING,
      PROSECUTION AND MAINTENANCE OF PATENT RIGHTS

     

    7.1  Patent
      Filing, Prosecution and Maintenance.
      The
      responsibility for filing, prosecution and maintaining Patent Rights shall
      be as
      follows:

     

    7.1.1  ROSETTA
      Patent Rights.
      ROSETTA, acting through patent counsel of its choice, shall be responsible,
      at
      its sole expense, for the preparation, filing, prosecution and maintenance
      of
      all ROSETTA Patent Rights. At ROSETTA’s request, AMBION shall cooperate with
      ROSETTA in all reasonable respects in connection with such preparation, filing,
      prosecution and maintenance of ROSETTA Patent Rights and Development Stage
      Patent Rights.

     

    7.1.2  AMBION
      Patent Rights.
      AMBION,
      acting through patent counsel of its choice, shall be responsible, at its own
      expense, for the preparation, filing, prosecution and maintenance of all AMBION
      Patent Rights. At AMBION’s request, ROSETTA shall cooperate, with and assist
      AMBION in all reasonable respects, at AMBION’s expense, in connection with such
      preparation, filing, prosecution and maintenance of AMBION Patent
      Rights.

     

    7.1.3  Joint
      Program Patent Rights.
      The
      Parties will cooperate through their respective Patent Coordinators to jointly
      select outside patent counsel to handle the filing, prosecution and maintenance
      of patents and patent applications claiming Joint Program Technology. ROSETTA
      shall control the prosecution of patent applications claiming inventions that
      are Joint Program Technology provided that, in addition to the provisions of
      Section 7.1.4, ROSETTA shall not take any action to amend or abandon any claim
      in a manner which would reduce the scope of coverage in the Field without the
      consent of AMBION, not to be unreasonably withheld, without affording AMBION
      the
      opportunity to retain such claim. The fees of counsel and the other costs and
      expenses related to patents and patent applications shall be shared equally
      by
      the Parties. Should one Party desire not to share in the cost of any such patent
      or patent applications, the other Party shall gain sole control of the filing,
      prosecution or maintenance of such patents or patent applications, which shall
      be deemed to be the Program Technology of such Party and such Party shall have
      sole responsibility for filing, prosecution or maintenance expenses with respect
      thereto.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        24

        
          

        

      

      
        
        

      

    

    7.1.4  Information
      and Cooperation.
      Except
      as otherwise provided herein, each Party responsible for the filing of the
      filing, prosecution and maintenance of Patent Rights under this Section 7.1
      (the
“filing Party”) shall (a) regularly provide the other Party with copies of all
      patent applications filed hereunder and other material submissions and
      correspondence with the patent offices, in sufficient time to allow for review
      and comment by the other Party and (b) provide the other Party and its patent
      counsel with an opportunity to consult with the filing Party and its patent
      counsel regarding the filing and contents of any such application, amendment,
      submission or response. The filing Party hereby agrees that the advice and
      suggestions of the other Party and its patent counsel shall be taken into
      reasonable consideration by the filing Party and its patent counsel in
      connection with each filing. Each Party shall, upon request from the filing
      Party and at the filing Party’s sole cost, reasonably cooperate with the filing
      Party in connection with such patent filing activities.

     

    7.1.5  Assignment
      of Patents.
      The
      assignment of any Patent Right under this Agreement shall include the right
      to
      enforce and collect damages for infringement of such Patent Right.

     

    7.2  Legal
      Actions.

     

    7.2.1  Third
      Party Infringement.

     

    (a)  Infringement.
      In the
      event either Party becomes aware of any possible infringement in the field
      of
      any ROSETTA Patent Rights, AMBION Patent Rights or Joint Program Patent Rights
      (a “Third Party Infringement”), that Party shall promptly notify the other Party
      and provide it with all details of such Third Party Infringement of which it
      is
      aware (each an “Infringement Notice”). ROSETTA shall have the first right and
      option, but not the obligation, to eliminate any such Third Party Infringement
      of ROSETTA Patent Rights within the Field, and AMBION shall have the first
      right
      and option, but not the obligation, to eliminate any Third Party Infringement
      of
      AMBION Patent Rights and/or of Joint Program Patent Rights within the Field,
      in
      any case, by taking reasonable steps, which may include the institution of
      legal
      proceedings; or the taking of other actions. All costs, including, without
      limitation, attorneys’ fees, relating to such legal proceedings or other actions
      shall be borne by the Party that assumes such obligation as described above.
      If
      ROSETTA does not take commercially reasonable steps to eliminate any Third
      Party
      Infringement of ROSETTA Patent Rights within three (3) months and such Third
      Party Infringement relates to the Field, then AMBION shall have the right and
      option to do so at its expense. AMBION does not take commercially reasonable
      steps to eliminate any Third Party Infringement of Joint Program Patent Rights
      within three (3) months and such Third Party Infringement relates to the Field,
      then ROSETTA shall have the right and option to do so at its expense. Neither
      Party shall settle any Third Party Infringement claim or proceeding under this
      Section 7.2.1(a) without the prior written consent of the other Party, which
      consent shall not be unreasonably withheld, conditioned or delayed.

     

    (b)  ParticipationEach
      Party shall have the right to participate, and be represented by counsel that
      it
      selects, in any legal proceedings or other action instituted under this Section
      7.2.1 by the other Party. If a Party with the right to initiate legal
      proceedings under Section 7.2.1 to eliminate a Third Party Infringement lacks
      standing to do so and the other Party has standing to initiate such legal
      proceedings, then the Party with standing shall initiate such legal proceedings
      at the request and expense of the other Party.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        25

        
          

        

      

      
        
        

      

    

    (c)  Joint
      Program Patent Rights.
      In the
      event of a Third Party Infringement of a Joint Program Patent Right outside
      the
      Field, the Parties shall enter into discussions as to whether and how to
      eliminate such Third Party Infringement. Each Party shall bear an equal share
      of
      the cost of any action, suit or proceeding instituted under this Section
      7.2.1(c). An equal share of all amounts recovered shall be received by each
      party. If the Parties are unable to determine whether and how to institute
      an
      action, suit or proceeding for Third Party Infringement of any such Joint
      Program Patent Right in the Diagnosis of any disease other than Prostate Cancer,
      either Party shall have the right to prosecute such Third Party Infringement,
      in
      which event that Party shall hear all of the expense and be entitled to retain
      all amounts that it recovers. If the Parties are unable to determine whether
      and
      how to institute an action, suit or proceeding for Third Party Infringement
      of
      any such Joint Program Patent Right in the Therapy of any disease or any other
      use of Joint Program Patent Rights, ROSETTA shall have the right to Prosecute
      such Third Party Infringement, in which event ROSETTA shall bear all of the
      expense and be entitled to retain all amounts that it recovers. Each Party
      shall
      have the right to be represented by counsel of its own selection in any action,
      suit or proceeding instituted under this Section 7.2.1(c) by the other Party.
      If
      a Party lacks standing and the other Party has standing to bring any such
      action, suit or proceeding, then the Party with standing shall bring such suit
      at the at the request and expense of the other Party.

     

    (d)  Cooperation.
      In any
      action, suit or proceeding instituted under this Section 7.2.1, the Parties
      shall cooperate with and assist each other in all reasonable respects. Upon
      the
      reasonable request of the Party instituting such action, suit or proceeding,
      the
      other Party shall join therein and shall be represented using counsel of its
      own
      choice, at the requesting Party’s expense.

     

    (e)  Recovery.
      Any
      amounts recovered-by ROSETTA pursuant to actions under Section 7.2.1(a) shall
      be
      allocated in the following order: (i) first, to reimburse ROSETTA and AMBION
      for
      their reasonable out-of-pocket expenses in making such recovery (which amounts
      shall be allocated pro rata if insufficient to covert the totality of such
      expenses); and (ii) then, 100% to ROSETTA. Any amounts recovered by AMBION
      pursuant to Section 7.2.1(a), whether by settlement or judgment, shall be
      allocated in the following order: (i) first, to reimburse AMBION and ROSETTA
      for
      their reasonable out-of-pocket expenses in making such recovery (which amounts
      shall be allocated pro rata if insufficient to cover the totality of such
      expenses); and (ii) then, to AMBION and ROSETTA in the same proportion as
      AMBION’s historic profits on Net Sales of the Collaboration Product or
      Collaboration Service affected by the Third Party Infringement bears to
      ROSETTA’s historic royalties hereunder in respect of such Net Sales, in each
      case as determined in good faith.

     

    7.2.2  Defense
      of Claims.

     

    (a)  Potential
      Infringement by AMBION.
      In the
      event that either Party becomes aware that the use in the Field by AMBION of
      any
      ROSETTA miRNA Sequence or Public miRNA Sequence infringes or may infringe the
      Patent Rights of a Third Party by reason of the conduct of the Development
      Program, or the Development or the Commercialization of any Collaboration
      Product or Collaboration Service (an “ANIBION Infringement”), AMBION may, in its
      discretion, at its cost and expense, (i) negotiate and enter into a license
      agreement or other arrangement with such Third Party to secure the necessary
      rights to patent(s) and/or patent application(s) owned by such Third Party
      which
      in AMBION’s reasonable opinion would present an issue of infringement by reason
      of AMBION ‘s manufacture, having manufactured, use, having used, offer for sale,
      sale, exportation or importation of a Collaboration Product or Collaboration
      Service, (ii) remove the infringing ROSETTA miRNA Sequence or Public miRNA
      Sequence from the Collaboration Product or Collaboration Service, or (iii)
      terminate sale of the Collaboration Product or Collaboration Service, which
      termination shall not be a breach of this Agreement, in which case AMBION shall
      provide ROSETTA with prompt written notice of same. Should AMBION fail to obtain
      such rights within twelve (12) months after having received notice from ROSETTA
      of such patent(s) and/or patent application(s), ROSETTA shall have the right
      but
      not the obligation, at its cost and expense, to negotiate and enter into a
      license agreement or other arrangement to obtain such rights under such Third
      Party patent(s) and/or patent application(s).

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        26

        
          

        

      

      
        
        

      

    

    (b)  Third
      Party Action.
      If any
      Third Party action, suit or proceeding is commenced against either Party
      alleging any such AMBION Infringement, (i) AMBION shall have the obligation
      to
      defend such action, suit or proceeding at its sole expense; (ii) ROSETTA shall
      have the right to separate counsel at its own expense in any such action, suit
      or proceeding; and (iii) the Parties shall cooperate with each other in all
      reasonable respects in any such action, suit or proceeding. Each Parry shall
      provide the other Party with prompt written notice of the commencement of any
      such suit, action or proceeding of which such Party becomes aware, and shall
      promptly furnish the other Party with a copy of each communication relating
      to
      the alleged AMBION Infringement that is received by such Party. For purposes
      of
      clarity, nothing in this Section 7.2.2 shall affect the right of ROSETTA to
      defend itself in any such action, suit or proceeding. However, AMBION shall
      have
      the sole authority to compromise, litigate, settle or otherwise dispose of
      any
      such suit, action or proceeding without ROSETTA’s prior written consent, if and
      only if the disposition of such suit, action or proceeding (i) does not subject
      ROSETTA to any financial obligation or duty whatsoever and (ii) does not require
      or imply any acknowledgement of fault on the part of ROSETTA. Any other
      disposition of such suit shall require ROSETTA’S prior written consent, which
      shall not be unreasonably withheld, conditioned or delayed.

     

    8.  TERM
      AND TERMINATION

     

    8.1  Term.
      This
      Agreement shall commence on the Effective Date and shall continue in full force
      and effect until (a) such time as AMBION is no longer Developing any
      Collaboration Products or Collaboration Services for use in the Field or (b)
      if,
      as of the time AMBION is no longer Developing any Collaboration Products or
      Collaboration Services for use in the field it is Commercializing one or more
      Collaboration Products or Collaboration Services, such time as the Royalty
      Term
      for all such Collaboration Products or Collaboration Services has ended, unless
      earlier terminated in accordance with the provisions of this Article 8 (the
      “Term”).

     

    8.2  Termination.
      This
      Agreement may be terminated at any time by either Party, or by the Party
      specified, as follows:

     

    8.2.1  Termination
      for Breach. Either Party may terminate this Agreement, effective immediately
      upon written notice to the other Party by giving sixty (60) days’ written notice
      to the Party committing any material breach of this Agreement (or, to the extent
      the material breach involves the failure to pay any amounts due under this
      Agreement upon thirty (3o) days’ written notice). Notwithstanding anything to
      the contrary set forth herein, (a) if the asserted breach is cured or shown
      to
      be non-existent within the sixty (60) or thirty (30) day cure period, the notice
      of breach hereunder shall be deemed automatically withdrawn and (b) a material
      default by a Party shall not give rise to the termination right under this
      Section 8.2,1 to the extent such material default arises from a Force Majeure
      event described in Section 12.10; provided, that the Party allegedly breaching
      the Agreement shall have the burden of demonstrating the occurrence of the
      Force
      Majeure event.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        27

        
          

        

      

      
        
        

      

    

    8.2.2  Termination
      for Insolvency.
      In the
      event that either Party files for protection under the bankruptcy laws, makes
      an
      assignment for the benefit of creditors, appoints or suffers appointment of
      a
      receiver or trustee over its property, file a petition under any bankruptcy
      or
      insolvency act or has any such petition filed against it which is not discharged
      within sixty (60) days of the filing thereof, then the other Party may terminate
      this Agreement effective immediately upon written notice to such Party. In
      connection therewith, all rights and licenses granted under this Agreement
      are,
      and shall be deemed to be, for purposes of Section 365(n) of the United states
      Bankruptcy Code, licenses of rights to “intellectual property” as defined under
      Section 101(56) of the United States Bankruptcy Code.

     

    8.3  Consequences
      of Termination of Agreement.
      In the
      event of the termination of this Agreement pursuant to Section 8.2 the following
      provisions shall apply, as applicable.

     

    8.3.1  Termination
      by ROSETTA Pursuant to Section 8.2.1.
      If this
      Agreement is terminated by ROSETTA pursuant to Section 8.2.1, the following,
      provisions shall apply:

     

    (a)  the
      licenses and rights granted to AMBION pursuant to Section 5.1 shall immediately
      terminate, and AMBION shall be deemed to have granted to ROSETTA, as of the
      date
      of termination, an exclusive (even as to AMBION), worldwide, royalty bearing
      license, with the rights to sublicense, under AMBION Technology and AMBION
      Patent Rights and AMBI.ON’S interest in Joint Program Technology and Joint
      Program Patent Rights, to Develop, have Developed, Commercialize and have
      Commercialized Collaboration Products and Collaboration Services then being
      Developed or Commercialized for use in the Field; provided, that if ROSETTA
      sells any such Collaboration Product or Collaboration Service itself, ROSETTA
      shall pay royalties to AMBION as set forth in Section 3.1, mutatis
      mutandis,
      and if
      ROSETTA licenses a Third Party to sell any such Collaboration Product or
      Collaboration Service, ROSETTA shall pay to AMBION [***] percent ([***]%) of
      all
      royalties received from such Third Party with respect to sales of such
      Collaboration Product or Collaboration Service.

     

    (b)  each
      Party shall promptly return all Confidential Information and Proprietary
      Materials of the Other Party that are not subject to a continuing license
      hereunder; provided that each Party may retain one copy of the Confidential
      Information of the other Party in its archives solely for the purpose of
      establishing the contents thereof and ensuring compliance with its obligations
      hereunder;

     

    (c)  upon-request
      of ROSETTA, AMBION shall promptly, and in any event within sixty (60) days
      after
      ROSETTA’s request: (i) transfer to ROSETTA all of its right, title and interest
      in all Regulatory Filings and Regulatory Approvals then in its name applicable
      to any Collaboration Product or Collaboration Service, and all material aspects
      of Confidential Information Controlled by it as of the date of termination
      relating to such Regulatory Filings and Regulatory Approvals; (ii) notify the
      applicable Regulatory Authorities and take any other action reasonably necessary
      to effect such transfer, and (iii) provide ROSETTA with copies all
      correspondence between. AMBION and such Regulatory Authorities relating to
      such
      Regulatory Filings and Regulatory Approvals; (iv) AMBION hereby grants to
      ROSETTA an irrevocable power of attorney, coupled with an interest, to take
      the
      actions set forth in this Section 8.3.1 (c) if AMBION does not no so within
      sixty (60) days of ROSETTA’s request.; and

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        28

        
          

        

      

      
        
        

      

    

    (d)  if
      AMBION
      has manufactured, is manufacturing or having manufactured any Collaboration
      Product as of the effective date of termination: (i) AMBION shall, if requested
      by ROSETTA, supply ROSETTA with its requirements for all such-Collaboration
      Product for up to thirty-six (36) months following such termination at a
      transfer price equal to AMBION’s fully burdened cast for the supply of such
      Collaboration Product, and (ii) within sixty days after ROSETTA’s request,
      AMBION shall provide to ROSETTA or its designee all information in its
      possession with respect to the manufacture of each such Collaboration
      Product.

     

    8.3.2  Termination
      by AMBION Pursuant to Section 8.2.1 or Section 8.2.2.
      If this
      Agreement is terminated by AMBION pursuant to Section 8.2.1 or Section
      8.2.2:

     

    (a)  AMBION
      shall continue to have the license and rights set forth in Section 5.1 to
      Develop Collaboration Products and Collaboration Services being Developed by
      AMBION as of the effective date of termination, if any, and to Commercialize
      and
      have Commercialized Collaboration Products and Collaboration Services being
      Commercialized by AMBION as of the effective date of termination, if any,
      subject to its continued payment of all royalty payments with reaped thereto;
      and

     

    (b)  each
      Party shall promptly return all Confidential Information and Proprietary
      Materials of the other Party that are not subject to a continuing license
      hereunder; provided that each Party may retain one copy of the Confidential
      Information of the ether Party in its archives solely for the purpose of
      establishing the contents thereof and ensuring compliance with its obligations
      hereunder.

     

    8.3.3  Termination
      by ROSETTA Pursuant to Section 8.2.2.
      If this
      Agreement is terminated by ROSETTA pursuant to Section 8.2.2; to the extent
      not
      prohibited by Applicable Laws:

     

    (a)  the
      license and rights set forth Section 5.1 shall survive solely as applied to
      Collaboration Products and Collaboration Services being Commercialized by AMBION
      as of the effective date of termination, if any, subject to AMBION’s continued
      payment of all royalty payments under and in accordance with this Agreement
      with
      respect thereto; and

     

    (b)  each
      Party shall promptly return all Confidential Information and Proprietary
      Materials of the other Party that are not subject to a continuing license
      hereunder; provided that each Party may retain one copy of the Confidential
      Information of the other Party in its archives solely for the purpose of
      establishing the contents thereof and ensuring compliance with its obligations
      hereunder.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        29

        
          

        

      

      
        
        

      

    

    8.4  Surviving
      Provisions.
      Termination or expiration of this Agreement for any reason shall be without
      prejudice to:

     

    (a)  the
      rights and obligations of the Parties provided in Sections 8.3 and 8.4 and
      Articles 4, 6, 7, 10, 11, and 12 (including all other Sections or Articles
      referenced in any such Section or Article and including Article 1) all of which
      shall survive such termination;

     

    (b)  ROSETTA’s
      rights to receive royalties for the duration of any applicable Royalty Term;
      and

     

    (c)  any
      either rights or remedies provided at law or equity which either party may
      otherwise have.

     

    9.  REPRESENTATIONS
      AND WARRANTIES

     

    9.1  Mutual
      Representations and Warranties.
      ROSETTA
      and AMBION each represents and warrants to the other, as of the Effective Date,
      as follows:

     

    9.1.1  Organization.
      It is a
      corporation duly organized, validly existing and in good standing under the
      laws
      of the jurisdiction of its organization, and has all requisite power and
      authority, corporate or otherwise, to execute, deliver and perform this
      Agreement.

     

    9.1.2  Authorization.
      The
      execution and delivery of this Agreement and the performance by it of the
      transactions contemplated hereby have been duly authorized by all necessary
      corporate action and will not violate (a) such Party’s certificate of
      incorporation or bylaws, (b) any agreement, instrument or contractual obligation
      to which such Party is bound in any material respect, (c) any requirement of
      any
      Applicable Law, or (d) any order, writ, judgment, injunction, decree,
      determination or award of any court or governmental agency presently in effect
      applicable to such Party.

     

    9.1.3  Binding
      Agreement.
      This
      Agreement is a legal, valid and binding obligation of such Party enforceable
      against it in accordance with its terms and conditions.

     

    9.1.4  No
      Inconsistent Obligation.
      It is
      not under any obligation, contractual or otherwise, to any Person that conflicts
      with or is inconsistent in any respect with the terms of this Agreement or
      that
      would impede the diligent and complete fulfillment of its obligations
      hereunder.

     

    9.2  Additional
      Representations of ROSETTA.
      ROSETTA
      further represents and warrants to AMBION, as of the Effective Date, as
      follows:

     

    9.2.1  Right
      to Technology.
      ROSETTA
      has the right to (a) use the Licensed Technology and Licensed Patent Rights
      existing as of the Effective Date as is necessary to fulfill its obligations
      under this Agreement; and (b) grant the licenses under the Licensed Patent
      Rights existing as of the Effective Date granted pursuant to this
      Agreement.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        30

        
          

        

      

      
        
        

      

    

    9.2.2  No
      Conflict.
      The
      grant to AMBION of the license to the Licensed Patent Rights existing as of
      the
      Effective Date contemplated by this Agreement will not conflict with any
      agreement to which ROSETTA is a party as of the Effective Date.

     

    10.  IDEMNIFICATION

     

    10.1  Idemnification
      of AMBION by ROSETTA.
      ROSETTA
      shall indemnify, defend and hold harmless AMBION, its Affiliates, their
      respective directors, officers, employees and agents, and their respective
      successors, heirs and assigns (the “AMBION Indemnitees”), against all
      liabilities, damages, losses and expenses (including reasonable attorneys’ fees
      and expenses of litigation), (collectively, “Losses”) incurred by or imposed
      upon the AMBION Indemnitees, or any one of them as a direct result of any
      claims, suits, actions, demands or judgments of Third Parties; including without
      limitation; personal injury and product liability matters and claims of
      suppliers and employees (collectively, “Claims”) arising out of any action by
      ROSETTA in the conduct of the Development Program; provided that, with respect
      to any Claim for which ROSETTA has an obligation to any AMBION Indemnitee
      pursuant to this Section 10.1 and AMBION has an obligation to any ROSETTA
      Indemnitee pursuant to Section 10.2, each Party shall indemnify each of the
      other Party’s indemnitees for its Losses to the extent of its responsibility for
      the facts underlying the Claim relative to the other Party.

     

    10.2  Indemnification
      of ROSETTA by AMBION.
      AMBION
      shall indemnify, defend and hold harmless ROSETTA, its Affiliates, their
      respective directors, officers, employees and agents and their respective
      successors, heirs and assigns (the “ROSETTA Indemnitees”), against any Losses
      incurred by or imposed upon the ROSETTA Indemnitees or any one of them, as
      a
      direct result of any Claims arising out of (a) any action AMBION in the conduct
      of the Development Program, (b) the Development by AMBION of any Collaboration
      Product or Collaboration Service, (c) the Commercialization (including, without
      limitation, the production, manufacture, promotion, import, sale or use by
      any
      Person) of any Collaboration Product or Collaboration Service that is
      manufactured or sold by AMBION or by an Affiliate, Sublicensee, Distributor
      or
      agent of AMBION; provided that with respect to any Claim for which ROSETTA
      has
      an obligation to any AMBION Indemnitee pursuant to Section 10,1 and AMBION
      has
      an obligation to any ROSETTA Indemnitee pursuant to this Section 10.2, each
      Party shall indemnify each of the other Party’s Indemnifities for its Losses to
      the extent of its responsibility for the facts underlying the Claim relative
      to
      the other Party.

     

    10.3  Conditions
      to Indemnification.
      Person
      seeking recovery under this Article 10 (the “Indemnified Party”) in respect of a
      Claim shall give prompt notice of such Claim to the Party from which-recovery
      is
      sought (the “Indemnifying Party”) and, provided that the Indemnifying Party is
      not contesting its obligation under this Article 1.0, shall permit the
      Indemnifying Party to control any litigation relating to such Claim and the
      disposition of such claim; provided that the Indemnifying Party shall act
      reasonably and in good faith with respect to all matters relating to the
      settlement or disposition of such Claim as the settlement or disposition relates
      to Parties being indemnified under, this Article 10. The Indemnifying Party
      may
      settle or otherwise resolve such claim without the prior written consent of
      the
      Indemnified Party if and only if the resolution of such claim (i) does not
      subject the Indemnified Party to any obligation or duty whatsoever and (ii)
      does
      not require or imply any acknowledgement of fault on the part of the Indemnified
      Party. The Indemnified Party shall cooperate with the Indemnifying Party in
      its
      defense of any such Claim in all reasonable respects and shall have the right
      to
      be present in person or through counsel at all legal proceedings with respect
      to
      such Claim. Any other disposition of such suit shall require ROSETTA’S prior
      written consent, which shall not be unreasonably withheld, conditioned or
      delayed,

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        31

        
          

        

      

      
        
        

      

    

    10.4  Warrant
      Disclaimer.
      EXCEPT
      AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY
      WARRANTY WITH RESPECT TO ANY TECHNOLOGY, GOODS, SERVICES, RIGHTS OR OTHER
      SUBJECT MATTER OF THIS AGREEMENT AND EACH PARTY HEREBY DISCLAIMS ALL WARRANTIES,
      EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY,
      FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT:

     

    10.5  No
      Warranty of Success.
      Nothing
      contained in this Agreement shall be construed as a warranty on the part of
      either Party that (a) the Development Program will yield any Collaboration
      Product or Collaboration Service or otherwise be successful or (b) the outcome
      of the Development Program will be commercially exploitable in any
      respect.

     

    10.6  Limited
      Liability.
      NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, NEITHER PARTY SHALL
      BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR (I) ANY SPECIAL,
      PUNITIVE, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, MCLUDING WITHOUT
      LIMITATION LOST PROFITS OR LOST REVENUES, OR (II) COST OF PROCUREMENT OF
      SUBSTITUTE GOODS, TECHNOLOGY OR SERVICES, WHETHER UNDER ANY CONTRACT, WARRANTY,
      NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY.

     

    10.7  Insurance.
      Not
      later than nine (9) months after the Effective Date, but in any event prior
      to
      use or testing of any product on humans, and at all times thereafter until
      the
      expiration of all applicable statutes of limitation pertaining to any
      manufacture, marketing, possession, use, sale of other disposition of any
      Collaboration Products or Collaboration Services, AMBION will, at its expense,
      obtain and maintain in full force and effect, comprehensive general liability
      insurance, including product liability insurance; against all claims,
      obligations, liabilities, and damages, based upon or arising out of actual
      or
      alleged bodily injury, personal injury, death, or any other damage to or loss
      of
      persons or property, caused by any such manufacture, marketing, possession,
      use,
      sale, or other disposition. Each such policy shall name ROSETTA as an additional
      insured party:

     

    11.  DISPUTE
      RESOLUTION

     

    11.1  Dispute
      Resolution.
      In the
      event of any dispute arising between the Parties in connection with this
      Agreement, the construction thereof, or the rights, duties or liabilities of
      either Party (each a “Disputed Matter”), the Disputed Matter shall be submitted
      to the Designated Senior Officers of the Parties for good faith resolution.
      In
      the event the Disputed Matter cannot be resolved by the good faith efforts
      of
      the Designated Senior Officers on or before thirty (30) days from the date
      such
      Disputed Matter is first presented for resolution, then such Disputed Matter
      shall be resolved by binding arbitration in accordance with the following
      procedures.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        32

        
          

        

      

      
        
        

      

    

    (a)  The
      arbitration shall be conducted by a panel of three (3) persons experienced
      in
      the pharmaceutical business who are independent of both Parties. Within thirty
      (30) days after initiation of arbitration, each Party shall select one person
      to
      act as arbitrator and the two Party-selected arbitrators shall select a third
      arbitrator within thirty (30) days of their appointment. If the arbitrators
      selected by the Parties are unable or fail to agree upon the third arbitrator,
      the-third arbitrator shall he appointed by the American Arbitration Association
      (“AAA” ). The place of arbitration shall be New York, New York, and all
      proceedings and communications shall be in English. Except as provided for
      differently herein, the arbitration shall be conducted under the rules of the
      AAA applicable to complex business disputes.

     

    (b)  Either
      Party may apply to the arbitrators for interim injunctive relief until the
      arbitration decision is rendered or the Disputed Matter is otherwise resolved.
      Either Party also may, without waiving any right or remedy under this Agreement,
      seek from any court having jurisdiction any injunctive or provisional relief
      necessary to protect the rights or property of that Party pending resolution
      of
      the Disputed matter pursuant to this Section 11.1. The arbitrators hall have
      no
      authority to award punitive or any other type of damages not measured by a
      Party’s compensatory damages. Each Party shall bear its own costs and expenses
      and attorneys’ fees, and the Party that does not prevail in the arbitration
      proceeding shall pay the arbitrators’ fees and, any administrative fees of
      arbitration.

     

    (c)  Except
      to
      the extent necessary to confirm an award or decision as may be required by
      Applicable Laws, neither a Party nor an arbitrator may disclose the existence,
      content, or results of an arbitration without the prior written consent of
      both
      Parties. In no event shall an arbitration be initiated after the date when
      commencement of a legal or equitable proceeding based on the Disputed Matter
      would be barred by the applicable New York statute of limitations.

     

    (d)  The
      Parties agree that, in the event an Arbitration Matter involving the alleged
      breach of this Agreement (including, without limitation, whether a Party has
      satisfied its diligence obligations hereunder), neither Party may terminate
      this
      Agreement until resolution of the Disputed Matter pursuant to this Section
      11.1.

     

    (e)  The
      Parties hereby agree that any disputed performance or suspended performance
      pending the resolution of an Disputed Matter that the arbitrators determine
      to
      be required to be performed by a Party must be completed within a reasonable
      time period following the final decision of the arbitrators.

     

    (f)  The
      Parties hereby agree that any monetary payment to be made by a Party pursuant
      to
      a decision of the arbitrators shall be made in United States dollars, free
      of
      any tax or other deduction. The Parties further agree that the decision of
      the
      arbitrators shall be the sole, exclusive and binding remedy between thorn
      regarding determination of Disputed Matters presented.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        33

        
          

        

      

      
        
        

      

    

    12.  MISCELLANEOUS

     

    12.1  Notices.
      All
      notices and communications shall be in writing and delivered personally or
      by
      courier providing evidence of delivery or mailed via certified mail, return
      receipt requested, addressed as follows, or to such other address as may be
      designated from time to time:

     

    If
      to
      AMBION:

    

    2130
      Woodward St.

    Austin,
      Texas 78744

    Telephone
      Number:(512) 651 0200

    Facsimile
      Number: (512) 651 0201

    Attention:
      Vice-President of Business Development

    cc:
      General Counsel

    

    if
      to
      ROSETTA;

    

    Rosetta
      Genomics, Ltd. 

    10
      Plaut
      Street

    Science
      Park

    Rehovot,
      Israel

    Tel:
      972-8-948-4755

    Fax:
      972-8-948-4766 

    Attention:
      Managing Director

    

    With
      a
      copy to:

    

    Mintz,
      Levin, Cohn, Ferris, Glovsky

    and
      Popeo, PC

    One
      Financial Center 

    Boston,
      Massachusetts 02111

    Attention:
      Jeffrey Wiesen

    Tel:
      (617) 542-6000 

    Fax:
      (617) 542-2241

    

    Except
      as
      otherwise expressly provided in this Agreement or mutually agreed in writing,
      any notice, communication or document (excluding payment) required to be given
      or made shall be deemed given or made and effective upon actual receipt or,
      if
      earlier, (a) three (3) business days after deposit with an
      internationally-recognized overnight express courier with changes prepaid,
      or
      (b) five (5) business days after mailed by certified, registered or regular
      mail, postage prepaid, in each case addressed to a Parties at its address stated
      above or, to such other address as such Party may designate by written notice
      in
      accordance with this Section 12.1.

     

    12.2  Governing
      Law.
      This
      Agreement shall be governed by and construed in accordance with the laws of
      the
      State of Now York (USA), without regard to the application of principles of
      conflicts of law.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        34

        
          

        

      

      
        
        

      

    

    12.3  Binding
      Effect.
      This
      Agreement shall be binding upon and inure to the benefit of the Parties and
      their respective legal representatives, successors and permitted
      assigns.

     

    12.4  Headings.
      Section
      and subsection headings are inserted for convenience of reference only and
      do
      not form a part of this Agreement.

     

    12.5  Counterparts.
      This
      Agreement may be executed simultaneously in two or more counterparts, each
      of
      which shall be deemed an original and both of which, together, shall constitute
      a single agreement.

     

    12.6  Amendment;
      Waiver.
      This
      Agreement may be amended, modified, superseded or canceled, and any of the
      terms
      of this Agreement maybe waived, only by a written instrument executed by each
      Party or, in the case of waiver, by the Party or Parties waiving compliance.
      The
      delay or failure of any Party at any time or times to require performance of
      any
      provisions shall in no manner affect the rights at a later time to enforce
      the
      same. No waiver by any Party of any condition or of the breach of any term
      contained in this Agreement, whether by conduct, or otherwise, in any one or
      more instances, shall be deemed to be, or considered as, a further or continuing
      waiver of any such condition or of the breach of such term or any other term
      of
      this Agreement.

     

    12.7  No
      Third Party Beneficiaries.
      Except
      as set forth in Sections 10.1 and 10.2, no Third Party (including, without
      limitation, employees of either Party) shall have or acquire any rights by
      reason of this Agreement.

     

    12.8  Purposes
      and Scope.
      The
      Parties hereto understand and agree that this Collaboration is limited to the
      activities, rights and obligations as set forth in this Agreement. Nothing
      in
      this Agreement shall be construed (a) to create or imply a general partnership
      between the Parties, (b) to make either Party the agent of the other for any
      purpose, (c) to alter, amend; supersede or vitiate any other arrangements
      between the Parties with respect to any subject matters not covered hereunder,
      (d) to give either Party the right to bind the other except as expressly set
      forth herein, (e) to create any duties or obligations between the Parties except
      as expressly set forth herein, or (f) to grant any director implied licenses
      or
      an other right other than as expressly set forth herein.

     

    12.9  Assignment
      and Successors.
      Neither
      this Agreement nor any obligation of a Party hereunder maybe assigned by either
      Party without the consent of the other Party, except that each Party may assign
      this Agreement and the rights, obligations and interests of such Party, in
      whole
      or in part, to any of its Affiliates, to any purchaser of all of its capital
      stock or assets and/or all of its assets to which this Agreement relates or
      to
      any successor corporation resulting from any merger or consolidation of such
      Party with or into such corporation.

     

    12.10  Force
      Majeure.
      Neither
      AMBION nor ROSETTA shall be liable for failure of or delay in performing
      obligations set forth in this Agreement, and neither shall be deemed in breach
      of its obligations, if such failure or delay is due to a Force Majeure. In
      event
      of such Force Majeure event, the Party affected thereby shall use reasonable
      efforts to cure or overcome the same and resume performance of its obligations
      hereunder.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        35

        
          

        

      

      
        
        

      

    

    12.11  Interpretation.
      The
      Parties hereto acknowledge and agree that: (a) each Party and its counsel
      reviewed and negotiated the terms and provisions of this Agreement and have
      contributed to its revision; (b) the rule of construction to the effect that
      any
      ambiguities are resolved against the drafting Party shall not be employed in
      the
      interpretation of this Agreement; and (c) the terms and provisions of this
      Agreement shall be construed fairly as to all Parties hereto and not in favor
      of
      or against any Party, regardless of which Party was generally responsible for
      the preparation of this Agreement.

     

    12.12  Integration;
      Severability.
      This
      Agreement and the Existing Agreements are the entire agreement with respect
      to
      the subject matter hereof and supersedes all other agreements and understandings
      between the Parties with respect to such subject matter. If any provision of
      this Agreement is or becomes invalid or is ruled invalid by any court of
      competent jurisdiction or is deemed unenforceable, it is the intention of the
      Parties that the remainder of the Agreement shall not be affected.

     

    12.13  Further
      Assurances.
      Each of
      ROSETTA and AMBION agrees to duly execute and deliver, or cause to be duly
      executed and delivered, such further instruments and do and cause to be done
      such further acts and things, including, without limitation, the filing of
      such
      additional assignments, agreements, documents and instruments, as the other
      Party may at any time and from time to time reasonably request in connection
      with this Agreement or to carry out more effectively the provisions and purposes
      of or to better assure and confer unto such other Party its rights and remedies
      under this Agreement.

     

    THE
      REST
      OF THIS PAGE WAS INTENTIONALLY LEFT BLANK.

     

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        36

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their
      duly authorized representatives.

    

    ROSETTA
      GENOMICS, LTD.

    

    By:_______________________________

    Name:
      Amir Avniel

    Title:
      President and COO

    

    

    AMBION
      DIAGNOSTICS, INC.

    

    By:_______________________________

    Name:
      Matt Winkler

    Title:
      CEO

    

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        37

        
          

        

      

      
        
        

      

    

    EXHIBIT
      A

    

    DEVELOPMENT
      PLAN

    

     

    Discovery
      Stage: [***]

     

    Rosetta
      and Ambion will [***] in the [***] of [***] and [***] to [***]Rosetta and Ambion
      will [***] the [***] of [***] that can be [***] that can be [***] to this and
      [***]

     

    [***]

     

    Rosetta
      and Ambion will [***]this could be [***] if the [***] after the [***] associated
      with the [***]. At this [***] from the two companies will [***] to the [***]
      below to [***] of the [***]each party shall[***] during the [***] after this
      [***] during the [***] after this [***]given limitations of the
      [***]

     

    Clinical
      Development Stage:

     

    [***]

     

    Phase
      1: [***]

     

    
      	
              (1)

            	
              [***]will
                be [***] upon during the [***] that represent the best opportunity
                for
                [***]

            

    

     

    
      	(2)	
              [***]
                from [***]

            

    

     

    
      	
              (5)

            	
              [***]
                upon at the [***]

            

    

     

    
      	
              (4)

            	
              [***]within
                the [***]

            

    

     

    
      	(5)	
              [***] [***]
                then proceed with [***]

            

    

     

    
      	Goals.	
              [***]
                that can be [***]

            

    

     

    Phase
      2: [***]

     

    
      	
              (l)

            	
              [***]
                to measure; [***] associated with each of
                the[***]

            

    

     

    
      	(2)	
              [***]
                with known [***]

            

    

     

    
      	
              (3)

            	
              [***]
                The number of [***] will be decided
                [***]

            

    

     

    
      	(4)	
              [***]
                from [***]

            

    

     

    
      	
              (5)

            	
              [***]
                from the [***] If the [***] appropriate [***] then proceed with the
                [***]
                with [***] to establish [***]

            

    

     

    Goals:
      [***]
      of
      the [***]Use these [***] of the [***]

    

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 406 of the Securities Act.

          
          

        

        
          A-1

          
            

          

        

        
          
          

          
          

        

      

    

    Phase
      3: [***]

     

    
      	(1)	
              [***]

            

    

     

    
      	(2)	
              [***]
                with [***]

            

    

     

    
      	(3)	
              [***]
                some or all [***] [***]

            

    

     

    
      	
              (4)

            	
              [***]
                appropriate [***] then [***] with [***] with
                [***]

            

    

     

    Goal:     
      [***] that can be [***] for the [***]

     

    Phase
      4: [***]

     

    
      	
              (1)

            	
              [***]
                with the [***] for the[***]

            

    

     

    
      	
              (2)

            	
              [***]
                that can [***] of the [***]

            

    

     

    
      	(3)	
              [***]
                into their [***]

            

    

     

    
      	
              (4)

            	
              [***]
                of the [***]

            

    

     

    
      	(5)	
              [***]
                as an [***]

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        A-2

        
          

        

      

      
        
        

        
        

      

    

    SCHEDULE
      1

     

    
 

    THIS
      SCHEDULE WAS INTENTIONALLY LEFT BLANK

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        Sched.

        
          

        

      

      
        
        

      

    

    SCHEDULE
      2

    LICENSED
      PATENT RIGHTS

    

    

      
        	
                App
                  No

              	
                Filed

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	 	 

      

    

     

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        Sched.
          2

        
          

        

      

      
        
        

      

    

    SCHEDULE
      3 

    

    COLLABORATION
      PRODUCTS

    

     

     

     

     

    
 

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        Sched.
          3

        
          

        

      

      
        
        

      

    

    SCHEDULE
      4

    

    ROSETTA
      MARKETING DEVELOPMENT ACTIVITIES

    

    
      	1.	
              ROSETTA
                will use [***] during the [***] from the
                [***]

            

    

    

    a.
       [***]
      of
      at [***]

    

    b. [***]
      of
      at [***] in at [***]

    

    c. [***],
      and

    

    d. [***]

    

    
      	
              2.

            	
              Provision
                by ROSETTA of [***] established by ROSETTA [***] until such time
                as [***]
                or other [***] for [***] by AMBION.

            

    

    

    
      	3.	
              [***]
                with AMBION [***]

            

    

    

     

     

     

     

     

    
 

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        Sched.
          4

        
          

        

      

      
        
        

      

    

    SCHEDULE
      5

    

    RESTRICTIONS
      ON USE

    

    NOTICE
      TO
      PURCHASE: LIMITED LICENSE:

    

    This
      product is sold under licensing arrangement between Ambion Diagnostics, Inc.
      and
      Rosetta Genomics, Ltd. The purchase price of this product includes limited,
      nontransferable rights under patents and/or pending patent applications owned
      by
      Rosetta Genomics to use the product for commercial purposes solely for (a)
      the
      determination of (i) the presence of Prostate cancer, (ii) the state,
      progression or severity of Prostate Cancer, or (iii) the effect on Prostate
      Cancer of a particular treatment; and/or (b) the selection of patients for
      a
      particular treatment with respect to applications may be obtained by contacting
      Rosetta Genomics, Director of Business Development BD@Rosettagenomics.com
      (Phone
      number to be added.)

    

     

     

     

     

     

    

      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 406 of the Securities Act.

          
          

        

        
          Sched.
            5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}]]